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Abstract
Homeostasis of the immune system is required for proper defense against pathogenic insult.
Cells of the innate and adaptive compartments provide a strictly regulated response to clear
infections while allowing for self-tolerance. Dysregulation of the components of the immune
system can lead to immunodeficiency, autoimmunity, and cancer. Key players of the immune
response are T, B, and NK cells, which become strongly activated by IL2 through its receptor. The
β subunit of the receptor becomes tyrosine, serine, and threonine phosphorylated upon induction
with IL2. Phosphorylation of tyrosine residues has been extensively studied, however, the putative
regulatory role of serine and threonine phosphorylation on IL2 signaling has yet to be
characterized. The first objective of this research was to identify novel phosphorylation sites on
IL2Rβ. Using immunoprecipitation combined with LC-MS/MS five novel IL2Rβ phosphorylation
sites, S268, T394, T450, S484, and S512 were identified. In an attempt to characterize T450 and
S512 phosphosites, phosphospecific antibodies were generated and found to be reliable new tools
to elucidate the role of T450 and S512 in IL2 signal transduction. Using these phosphospecific
antibodies, the phosphorylation status of T450 in response to physiological stimuli was
investigated. The phosphorylation of IL2Rβ T450 occurred in multiple cell types, including
primary human PBMCs, with profiles indicating a general mechanism of IL2Rβ activation.
Kinase/phosphatase inhibition studies along with siRNA or purified phosphatases allowed for the
identification of ERK1/2 as the kinases that phosphorylate the receptor while PP1 was the
phosphatase that mediates its dephosphorylation. Finally, IL2 induced IL2Rβ T450 was found to
have a positive regulatory role as demonstrated in a HEK293 reconstitution system using WT or
amino acid substitution within IL2Rβ. We assessed the effect of IL2 induced T450
phosphorylation in the assembly of the IL2R complex and the activation of key signaling
molecules by immunoprecipitation and Western blot analysis. Phosphorylation of T450 was found
to be important for IL2R complex formation, recruitment of JAK3, full activation of STAT5 and
AKT. These results suggest a new target to modulate T-cells with therapeutic potential.
vi
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CHAPTER 1
Introduction
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1.1

IMMUNE RESPONSE AND LYMPHOCYTE ACTIVATION
Homeostasis of the immune system is required for proper defense against pathogenic insult.

The first line of defense, innate immunity, is mediated through cells of myeloid origin, including
granulocytes, monocytes/macrophages, and natural killer (NK) cells, while the adaptive immune
response relies on the activation of B and T lymphocytes and their development into mature
functioning antibody producing and effector cells respectively. Cells of the innate and adaptive
compartments provide a strictly regulated response to clear infecting agents while allowing for
self-tolerance [1]. Dysregulation of the components of the immune system can lead to
immunodeficiency, autoimmunity, and cancer [2].
B and T lymphocytes require activation in order to differentiate and proliferate. T cells
become activated through the T cell receptor (TCR) complex which includes molecules for antigen
recognition, adhesion, and signal transduction. The TCR recognizes an antigen associated to the
major histocompatibility complex (MHC) molecule on antigen presenting cells (APC). Adhesion
and signal transduction is mediated by the cluster of differentiation (CD) 4 and CD8 on T cells as
well as the co-stimulatory receptor CD28, which binds to its ligand B7 (CD80) on APC [1]. These
and other co-stimulatory interactions induce the production and secretion of cytokines like
interleukin 2 (IL2) which bind their corresponding receptors in an autocrine or paracrine manner.
Together, these events provide the three signals required for full activation of T cells and initiation
of signaling cascades that that drive differentiation, proliferation, and cell survival [3].
B cell activation relies on antigen recognition by the B cell receptor (BCR).
Immunoglobulins (Ig) on its membrane bind the antigen and induce phosphorylation of
immunoreceptor tyrosine-based activation motifs (ITAMs) on IgGα and IgGβ peptides. This
initiates signaling events that lead to transcription of genes involved in B cell proliferation and
differentiation. B cells can also function as APC. Once the antigen is internalized and processed,
it is presented to T helper cells through a MHC class II molecule. The T helper cell will then
produce and secrete cytokines that will stimulate proliferation and differentiation of B cells [4].
Other important players of immune response are NK cells. They have the ability to recognize and
2

kill infected as well as cancer cells without stimulation by antigen and are considered part of innate
immune response [5] although recent reports have confirmed memory cell-like functions,
suggesting a role in adaptive immunity [6]. NK cells, like T and B cells, are strongly activated by
IL2.
1.2

INTERLEUKIN 2
IL2, originally called T cell growth factor, is a cytokine produced and secreted primarily

by activated helper T (CD4+ T) cells in secondary lymphoid organs, although it can also be
expressed in other cell types including cytotoxic (CD8+ T), NK, dendritic, and mast cells [7, 8].
Its structure is comprised of four alpha helices with a molecular weight of 15 kDa [9]. IL2 activates
different subsets of T cells that include helper, regulatory, suppressor, and cytotoxic [10]. In
addition, IL2 induces B cell proliferation and differentiation, as well as Ig secretion [10, 11].
Moreover, IL2 promotes differentiation and a heightened activity of NK cells [12] [10] and
activation induced cell death (AICD) of antigen activated T cells after clearance of antigen [13].
The main transcription factors involved in IL2 gene regulation include nuclear factor of activated
T-cells (NFAT), activating protein 1 (AP-1), NF-KappaB, CREB/CREM and BLIMP [14-16]. One
of the main targets of IL2’s signal transduction is the gene forkhead box P3 (FOXP3) on Treg
cells; blockade of this signaling hinders development and function of Tregs which results in
autoimmunity [17]. The cellular responses to IL2 stimulation are mediated through the IL2
receptor (IL2R) complex and cellular effectors unique to each cell type.
1.3

IL2 RECEPTOR
The IL2R is composed of three subunits or chains: IL2Rα (CD25), IL2Rβ (CD122), and γc

(CD132). Subunit α is considered to be the low affinity receptor (Kd ≈ 10 nM) [18] and is expressed
in primitive T cells prior to undergoing TCRβ rearrangement, and on mature B cells after activation
of the BCR [19]; expression of β and γc form the intermediate affinity IL2R (Kd ≈ 1 nM) that is
observed on resting T cells, macrophages, NK cells and immature dendritic cells [20] [21]; the
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highest binding affinity (Kd ≈ 10 pM) occurs when α, β, and γc subunits bind IL2, as is observed
on activated T cells [18, 22] and mature DCs [21].
Binding of IL2 to the high affinity IL2R possibly occurs in a stepwise fashion: first, the α
subunit of the receptor binds and induces a conformational change within IL2 which heightens its
ability to bind the β subunit by twofold; after recruitment and binding of the IL2/IL2Rα complex
to the β subunit, the γc subunit is brought to close proximity and binds the complex through
interaction with IL2 and the β chain [23]. The biological effects of IL2 in vivo appear to be
mediated by the high affinity receptor since studies of IL2 or IL2Rα deficient mice show a similar
phenotype that includes enlarged lymph nodes, severe anemia, increased erythropoiesis, and bowel
disease [20]; T cells were found to be responsible for such conditions, since IL2-/- nude mice failed
to develop these diseases [24], pointing to the negative regulation of the peripheral lymphoid
compartment as the main role of IL2/IL2R in vivo [20].
IL2Rα is an affinity conferring chain of the IL2R for IL2. The α chain is not involved in
signal transduction due to a short cytoplasmic tail [25] and it is not shared with any other cytokine
receptors, although it is structurally similar to IL15Rα [16, 26]. IL2Rβ on the other hand is
involved in signal transduction and it is shared with the IL15R [26, 27]. IL2R γ is also involved in
signal transduction and it is known as γc or the gamma common chain since it is shared by the
receptors for IL4, IL7, IL9, IL15 and IL21, also known as the IL2 family cytokines [20, 22, 28].
Both the IL2Rβ and the γc chain belong to the type I cytokine receptor family: they have two
fibronectin III domains, form two disulfide bonds in the N-terminal domain, and contain the
WSXWS motif near the transmembrane region[22]. Neither the β subunit nor the γc chain contain
intrinsic catalytic activity and they both require activation by receptor-associated kinases to initiate
signal transduction. The β and γc subunits of the IL2 receptor are shared with the IL15 receptor
(Fig. 1.1).

4

Figure 1.1: IL2 and IL15 share the IL2R β and γc subunits. IL2Rα and IL15Rα confer
affinity to IL2 and IL15 respectively. IL2 acts in an autocrine or paracrine fashion and can bind
the receptor in cis or trans, while IL15 has to be presented in trans by IL15Rα to the
intermediate affinity IL2R.
5

The fully activated IL2R complex, including IL2, can be endocytosed by a clathrinindependent dynamin-dependent mechanism that involves PI3K [29]. After endocytosis occurs,
the α subunit is presumably transported through the early endosomal compartment and recycled
back to the plasma membrane. IL2Rβ/γc subunits are transported through the early endosomal
compartment possibly for recycling and to late endocytic vesicles and lysosomes for degradation
[30, 31].

1.3.1 IL2 Receptor Structure
IL2R
IL2Rα is a 55 kDa, 272 amino acids (AA) glycoprotein encoded on chromosome 10p1415 [10, 32]. It is expressed on monocytes as well as on T, NK, and mature B cells after BCR
stimulation [16]. IL2Rα’s extracellular domain is composed of 219 AA, and it contains two “sushilike” (small β-sheet sandwich) domains separated by a linker domain that is bent -90° [33]. The
transmembrane domain contains 19 AA and the cytoplasmic domain 13 AA, rendering it unable
to participate in signal transduction [25].
IL2R
IL2Rβ is encoded by 10 exons that span nearly 21 Kb localized on chromosome 22q13.1
[16, 34, 35]. It is expressed on neutrophils, T, B, NK, monocytes and some dendritic cells. Factors
that stimulate its expression include IL2, IL4, phytohemagglutinin (PHA), anti-CD3, anti-CD28,
a combination of anti-CD2 and anti-CD28 antibodies, and protein kinase C activator phorbol 12myristate 13-acetate [16]. IL2Rβ is a transmembrane protein of 551 AA in length with a molecular
weight of 75kDa. It does not contain intrinsic catalytic activity, hence requires activation by
receptor-associated kinases for initiation of signal transduction. It belongs to the type-I cytokine
receptor family; the extracellular domain which spans from AA 1 to 240 [36] contains two
fribronectin-III domains which are characterized by a β-sandwich sheet, connected by a helical
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linker bent at about 90 degrees. The amino terminal domain forms two disulfide bonds and it
contains the WSXWS motif near the transmembrane domain [20, 22] (Fig. 1.2).
The cytoplasmic domain of IL2Rβ is divided into three main regions: membrane proximal,
A (acidic) and H (half). The membrane proximal region, also called S region, is rich in serine
residues and contains two motifs common to hematopoietic cytokine receptors named box 1
(LKCNTPDPS) and box 2 (PLEVLERDKV) to which Janus tyrosine kinase (JAK) 1 and JAK3
bind [20, 37, 38]. A variable region called V box connects these two domains [37]. Both Box 1
and 2 are important for JAK1 binding and activation [38] while deletion of Box 2 eliminates
activation of Jak1 and Jak3 and the signaling events downstream of the receptor [20] (Figure 1.2).
The A (acidic) region of the receptor contains four tyrosine residues: Y338, Y355, Y358,
and Y361.

Upon activation and dimerization of IL2R, Y338 on the β chain becomes

phosphorylated and serves as a docking site for molecules that recognize phosphotyrosine-binding
domains (PTB), like the adaptor molecule SHC [20]. In addition, the A region contains the SRCfamily tyrosine kinases Lck, Fyn, and Lyn binding sites [20, 37, 39]. The A region can be deleted
from the receptor without affecting proliferation and JAK activation as long as the H region is
present [20]. However, NK cells from mice that express IL2Rβ that lack the A region do not exert
their cytotoxic function and T cells show enhanced proliferation due to sustained tyrosine
phosphorylation of β chain and longer binding of Signal Transducer and Activator of Transcription
(STATs) to DNA [40]. In addition, the A region is needed for IL2 mediated inhibition of
erythropoietin induced globin gene expression [41]. These results suggest a negative regulatory
function for the A region (Figure 2B).
The H region comprises half of IL2Rβ cytoplasmic domain. It contains two tyrosine
residues Y392 and Y510, which are phosphorylated and serve as docking sites for STAT5 [20,
37]. Mice that express IL2Rβ lacking the H region fail to produce NK cells, γδ T cells, and their
T cells do not to respond to low concentrations of IL2 presumably because STAT5 and STAT3
activation is impaired, leading to down-regulation of IL2Rα [40]. Later studies showed that a
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minimum receptor including Box 1 and 2 along with one STAT5 docking site and the region
between Y392 and Y510 is essential for expression of IL2Rα [42] (Figure 2B).
Mice that fail to express IL2Rβ die at about 12 weeks of age, after developing autoimmune
hemolytic anemia; they present an irregular immunoglobulin profile, dysregulated T cell activation
and B cell differentiation, and lack NK and CD4+ CD25+ regulatory T cells [16].
Gamma Common Chain
The gamma common chain (γc)is a 64 KDa protein composed of 369 amino acids encoded
on chromosome Xq13 [20]. It is expressed on NK, B, CD4+ and CD8+ T cells, neutrophils,
granulocytes, monocytes and macrophages [20]. Like IL2Rβ, the γc chain belongs to the type-I
cytokine receptor family, has fibronectin-III domains, three disulfide bonds [22], the WSXWS
motif, and contains no intrinsic catalytic activity [20]. The cytoplasmic domain of γc contains a
box 1 motif and a region with slight homology to box 2 from the β chain. This region is necessary
for JAK3 binding and activation, which is not affected by deletion of the rest of the γc chain [20].
The γc chain has a greater interaction with IL2Rβ than with α or IL2 [22]. Mutations in the γc chain
lead to X-linked severe combined immunodeficiency (X-SCID) in humans [43]. Mice lacking the
γc chain exhibit under developed thymus, a small B cell population and no NK, γδ cells, gutassociated lymphoid tissue, dendritic epidermal T cells, or peripheral lymph nodes [16].

8

Figure 1.2: IL2Rβ Domain Architecture. Representation of IL2Rβ chain. Cytoplasmic
domain shows known phosphorylation sites. Numbers indicate amino acid residues of human
IL-2Rβ. Putative binding sites for JAK1, JAK3, STAT5 and SHC along with binding sites for
LCK, FYN, and LYN are indicated.
9

1.4

IL2 AND ACTIVATION OF SIGNAL TRANSDUCTION PATHWAYS
Signal transduction pathways initiated following binding of IL2 to the receptor include

JAK/STAT, RAS/RAF/MEK/ERK, and PI3K/AKT [20, 31]. The signaling cascades involved in
these pathways are possible through phosphorylation; the addition of a phosphate group to a
substrate by a kinase is an essential post-translational modification event that regulates a large
number of proteins. Phosphorylation promotes activation of enzymes and can be regarded as an
“on/off” switch in signal transduction pathways due to its reversible and transitory character. In
addition, phosphorylation can alter a protein’s cellular localization and substrate binding affinity.
About one third of the human proteome can be phosphorylated [44] and it is estimated that 2-4%
of the genome codes for kinases and phosphatases, the enzymes in charge of de-phosphorylating
proteins [45].
1.4.1 JAK/STAT Pathway
Engagement of IL2 to the IL2R induces activation of the JAK/STAT pathway. When IL2
comes in close proximity to the receptor, JAK1 and JAK3 are recruited and bind IL2Rβ and γc
respectively. Once activated through autophosphorylation they tyrosine phosphorylate the
receptor, providing docking sites for STATs. STATs bind phosphorylated tyrosines on the
receptor through their SRC homology 2 (SH2) domains, become tyrosine and serine
phosphorylated, and form homo- or heterodimers which translocate to the nucleus to initiate gene
transcription [3].
JAKs
Many cytokines signaling pathways are dependent upon JAKs. There are four JAK family
members: JAK1, JAK2, JAK3, and TYK2. All are ubiquitously expressed except JAK3 which is
confined to immune cells, mostly those of lymphoid origin. They have seven JAK homology (JH)
domains. Their kinase activity is harbored in the JH1 domain, while JH2 contains a pseudokinase
that regulates kinase activity and binds substrates. JH3 through JH7 are involved in JAK/receptor
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binding, with JH4 containing a SH2 domain that binds to a phosphotyrosine on different proteins
[3].
JAK1 and JAK3 are the only JAKs involved in the IL2R signaling. There is constitutive
association of JAK1 to IL2Rβ and JAK3 to the γc chain through the box 1 and box 2 motifs in the
membrane proximal region [20]. After stimulation of the receptor with IL2, JAK1 and JAK3 are
activated via autophosphorylation and then tyrosine phosphorylate the receptor to initiate a cascade
of signaling events. In vitro studies have revealed that if JAK3 loses its catalytic activity, JAK1
cannot become activated; although if JAK1 is inactive, JAK3 can still become activated [20].
Studies in mice showed that JAK1 deficiency renders B and T cells unable to respond to survival
signals, which leads to a SCID phenotype due to low numbers of mature T and B cells, pre B cells,
and thymocytes. Most mice with a JAK1 knockdown die perinatally [3, 46].
JAK3 is essential for lymphoid tissue function. It is expressed in T, B, NK, and monocytic
cells [47]. Disruption of JAK3 catalytic activity in vivo results in a lower level of tyrosine
phosphorylation of IL2Rβ, JAK1, SHC, and STAT5 [48]. JAK3 associates with and activates the
γc to initiate signal transduction. Deficiency in its expression in humans or mutations in its kinase,
pseudokinase or the SH2 like domain that prevent its phosphorylation, produce a phenotype similar
to the one caused by mutations in the γc chain. Signaling of IL4, IL7, IL9, IL15 and IL21 is severely
affected and SCID is developed [48, 49].
Tyrosine phosphorylation of the IL2R and JAKs, allows for recruitment, docking and
activation of STATs transcription factors that regulate genes associated with proliferation and
survival of cells (Fig. 1.3).
STATs
STATs are a family of transcription factors localized in the cytoplasm that require
phosphorylation of specific tyrosine residues that bind a reciprocal STAT SH2 domain to become
activated, dimerize and translocate to the nucleus to regulate transcription. STAT proteins contain
six domains: an N-terminal domain, a coiled coil domain, important for protein-protein interaction,
11

DNA binding domain, linker domain, an SH2 domain for docking to receptor and dimer binding,
and a trans-activation domain which recruits coactivators and promotes transcriptional activity
[50]. There are seven STAT proteins: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and
STAT6 [3]. STAT2, STAT4, and STAT6 are involved in specific functions of B and T cells.
STAT1, STAT3, STAT5A, and STAT5B contribute to cell cycle progression and protection
against apoptosis of lymphocytes. The main STATs involved in IL2R signaling are the highly
homologous STAT5A and STAT5B [37]. After activation of the IL2R and recruitment and
activation of JAK1 and JAK3, STAT5 proteins dock on phosphorylated Y338, Y392, and Y510
within IL2Rβ and become tyrosine and serine phosphorylated themselves [51]. Mutants lacking
these tyrosine residues are not able to fully activate STATs even though JAK1 and JAK3 present
normal function and activation [20]. STAT5A is phosphorylated on Y-694 while STAT5B at Y699. After activation, STAT5A and STAT5B are released from the receptor and form homo or
heterodimers that translocate to the nucleus and in conjunction with other elements and coactivators, initiate transcription of genes involved in regulation of cell cycle like cyclin D1 and
D2, the cyclin-dependent kinase (CDK) inhibitor p21WAF/Cip1 and p27kip, as well as the
antiapoptotic BCL-XL and BCL-2 [51]. In addition, STAT5 is involved in the transcription of
IL2Rα, and the apoptotic inducing Fas ligand (FasL), which is implicated in AICD [37].
Studies with STAT5 knockout mice have revealed defective cytokine induced proliferation
of T and NK cells on animals that do not express STAT5A with females failing to lactate. When
STAT5B is knocked down, male mice are smaller and the liver gene expression profile is
comparable to their female counterpart [51]. Knockdown of both STAT5A and STAT5B results
in smaller mice and infertile females. NK cells are absent [52], T cells fail to proliferate in response
to IL2, and autoimmunity is developed [3] because of lack of T regulatory cells to maintain selftolerance.
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JAK/STAT Pathway Regulation
Regulation of the JAK/STAT pathway occurs through several mechanisms. Some
regulatory molecules like suppressor of cytokine signaling (SOCS) block the interaction of
phosphotyrosine residues on receptors with JAKs or STATs. Other, like protein tyrosine
phosphatases (PTPs) have the ability to dephosphorylate such residues, inactivating the receptor.
In addition, there are several post-translational modifications that regulate activity of the proteins
or target them for degradation (Figure 3).
There are eight members of the SOCS family of proteins, SOCS1-SOCS7 and cytokine
inducible SH2 domain protein (CIS). SOCS1-SOCS3 and CIS are induced by cytokines and
regulate JAK/STAT by negative feedback inhibition. SOCS proteins contain a conserved SH2
domain within the variable amino terminal, and a SOCS box in its carboxyl end. They act by
recognizing and binding phosphotyrosine residues through their SH2 domain. SOCS1 and SOCS3
have been shown to be involved in regulation of immune function; they inhibit activity of JAKs
and STATs respectively by binding to the cytokine receptor docking sites [53]. In addition, SOCS3
is phosphorylated by JAK1, inhibits phosphorylation and activation of JAK1 and STAT5, and
prevents IL2 induced cell proliferation [54]. The protein inhibitor of activated STATs (PIAS)
family of proteins regulates STATs by preventing their binding to DNA or by acting as ligases to
facilitate SUMOylation [55].
JAKs are regulated by the protein tyrosine phosphatases SHP1, SHP2, CD45, PTP1B and
T-cell PTP (TCPTP). SHP1 and SHP2 contain an SH2 domain and both are capable of acting on
JAK1. The transmembrane tyrosine phosphatase CD45 has been shown to dephosphorylate all the
JAKs while TCPTP acts on JAK1 and JAK3 [53]. The phosphatase SHP2 can also act on STAT5,
reverting it into its inactive form and out of the nucleus. In addition, it removes phosphates from
serine and tyrosine residues on STAT1 [53]. Protein phosphatase 2A (PP2A) is involved in the
regulation of the JAK3/STAT5 pathway by dephosphorylating serine residues on JAK3 and
STAT5, and serine/threonine on IL2Rβ; blockade of PP2A results in augmented serine/threonine
phosphorylation and reduced tyrosine phosphorylation [56].
13

Post-translational modifications other than phosphorylation have also been reported to be
involved in the JAK/STAT pathway, including ubiquitylation and ISGylation (the conjugation of
interferon stimulated gene 15). JAK2 and γc chain can be ubiquitilated [53, 57] while JAK1 and
STAT1 can be ISGylated [53]. Although ubiquitylation and ISGylation are involved in regulation
of several pathways, more studies are needed in order to determine their role in JAK/STAT
signaling.
STATs can not only be tyrosine and serine phosphorylated, ubiquitylated and ISGylated,
but also acetylated, methylated and SUMOylated [53]. All of these post-translational modifications
are involved in their regulation. However, the extent to which they regulate the different STATs
remains to be elucidated.
1.4.2 RAS/RAF/MEK/ERK Pathway
Engagement of IL2 to IL2R results in recruitment of JAKs, which phosphorylate tyrosine
residues on themselves and on the β and γ subunits of the receptor. These phosphorylated tyrosines
not only serve as docking sites for STATs, but are also recognized by other proteins.
Phosphorylation of tyrosine residue 338 on IL2Rβ allows for recognition and binding of the
adaptor molecule SHC through its PTB domain. SHC is activated through tyrosine
phosphorylation and recruits the adaptor protein growth factor receptor-bound protein 2 (GRB2),
and son of sevenless (SOS), a nucleotide exchange factor that promotes exchange of GDP to GTP
on RAS to activate it [37]. Once RAS is activated, the serine/threonine kinase RAF is recruited
and activates MEK, another serine/threonine kinase that phosophorylates and activates mitogen
activated protein kinase (MAPK) and extracellular signal regulated protein kinase (ERK), which
then phosphorylate and activate different transcription factors involved in cell survival and
apoptosis. ERK activates the transcription factor MYC, involved in cell proliferation and
chromatin remodeling; JUN and FOS, involved in differentiation, proliferation, and apoptosis;
TOB, an antiproliferative transcription factor; and MAP kinase-interacting serine/threonine kinase
(MNK) among others [58]. The anti-apoptotic genes BCL-2 and BCL-XL are induced through
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MAPK, which is also involved in activation of the PI3K pathway [37]. In vitro studies revealed
that the A region on IL2Rβ has been found to be indispensable for SHC, RAS, and MAPK
activation and induction of the proto-oncogenes C-FOS and C-JUN; however, activation of SHC
appears to be enough for the signaling cascade to occur [20]. The RAS/RAF/MEK/ERK pathway
activates several genes involved in
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Figure 1.3: Activation of IL2 dependent pathways. Upon binding of IL2 to the high affinity
IL2R, JAK1 and JAK3 are activated via autophosphorylation and then tyrosine phosphorylate
the receptor. This allows for recruitment, docking and activation of STAT transcription factors,
which dimerize and translocate to the nucleus to regulate genes associated with proliferation
and cell survival. Phosphorylation of tyrosine residue 338 on IL2Rβ allows for recognition by
the adaptor molecule SHC through its PTB domain. SHC recruits GRB2 and SOS to activate
RAS, which recruits RAF to activate MEK, which in turns activates MAPK and ERK, which
transcribe genes involved in cell survival and apoptosis. The PI3K/AKT pathway is also
activated through SHC. Once PI3K is activated it phosphorylates PIP2 to make PIP3, which
recruits PDK1 to phosphorylate AKT. Target proteins phosphorylated by AKT include
transcription factors involved in cell cycle control, tumor suppression, and proliferation.
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proliferation and cell survival although some studies in vitro have shown their signals to be
redundant with signals activated through IL2 like the JAK/STAT pathway (Figure 3).
Negative regulation of the RAS/RAF/MEK/ERK pathway is far from straightforward since
the components of the pathway are controlled by different factors. Activated ERK induces
feedback phosphorylation of SOS to prevent RAS from being activated and signal transduction to
occur. RAF-1 is regulated by auto-inhibition and serine phosphorylation through AKT. In addition,
the RAS family member RAP1 binds RAF-1 and prevents its interaction with RAS. The regulatory
molecule 14-3-3 has also been implicated in RAF-1 regulation and RAF Kinase Inhibitor Protein
(RKIP) prevents RAF-1 from phosphorylating MEK by preventing their interaction. ERK1 and 2
are inactivated and anchored in the cytosol by the protein tyrosine phosphatases PTP-SL and
HePTP [59]. Additionally, SHC has been found to interact with ERK, regulating its activation in
the absence of stimuli [60].
1.4.3 PI3K/AKT Pathway
In addition to activation of JAK/STAT and RAS/RAF/MEK/ERK pathways, signaling of
IL2 through IL2R activates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which is
involved in signaling for proliferation and cell survival. Once PI3K is activated it phosphorylates
phosphatidylinositol-4,5-diphosphate (PIP2) to make phosphatidylinositol-3,4,5-triphosphate
(PIP3), which recruits phosphoinositide dependent protein kinase 1 (PDK1) to phosphorylate
AKT. Target proteins phosphorylated by AKT include Checkpoint Kinase 1 (CHK1), involved in
cell cycle control; Murine Double Minute (MDM2), a regulator of p53 tumor suppressor; BCL-2
Associated Death Promoter (BAD); Forkhead Box O (FOXO) family of transcription factors,
involved in proliferation and stress tolerance; Tuberous Sclerosis Complex 2 (TSC2), implicated
in tumor suppression; and Mammalian Target of Rapamycin (MTOR), a serine/threonine kinase
critical for cell growth and survival [61] (Fig. 1.3). In addition, AKT can stimulate activity of
NFκB to allow transcription of genes involved in cell survival. Induction of PI3K by IL2 also
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regulates the activity of the transcription factor E2F, which acts on dihydrofolate reductase and
cyclin E genes, which regulate cell cycle progression from G1 to S; In addition, it upregulates of
p70 S6 kinase activity through MTOR [61], which phosphorylates the S6 component of the 40S
ribosomal subunit, hence increasing transcription of genes related to cell division [37]. The
PI3K/AKT pathway activates different sets of genes on different cells [37]. Importantly, the PI3K
pathway is differentially activated by IL2 and IL15. IL2 [62].
Negative regulation of the PI3K/AKT pathway is mainly accomplished by the phosphatase
and tensin homologue deleted on chromosome 10 (PTEN), a protein and lipid phosphatase in
charge of dephosphorylating PIP3 to PIP2 [63]. Absence or malfunction of PTEN leads to a
constitutive activation of the PI3K/AKT pathway and has been linked to the development of cancer
[63]. Other factors that may be involved in the regulation of the PI3K/AKT pathway include SH2
containing inositol phosphatase (SHIP), which is able to dephosphorylate PIP3, and carboxyl
terminal modulating protein (CTMP), which binds AKT to reduce its activity [63].
1.4.4 Other Kinases Involved in IL2 Signaling
Although JAKs are the main tyrosine kinases involved in IL2R signaling, other
tyrosine kinases have been found to be associated with the receptor, including lymphocyte-specific
protein tyrosine kinase (LCK), spleen tyrosine kinase (SYK), and the tyrosine kinase LYN [20].
LCK is mainly involved in TCR signaling; however, it has been found to be constitutively
associated to the A region of IL2Rβ and its activation is independent of JAK3, and although it does
heighten STAT activation it could be through a different receptor other than IL2R [64]. SYK on
the other hand, requires JAK3 for activation, which appears to be mediated by JAK1. In addition,
SYK is dispensable for IL2 induced activation of STAT [64]. LYN is expressed mainly in myeloid
and B cells, and it is involved in the activation of several proteins including PI3K, MAPK, JAKs,
STATs, and SYK. LYN interacts with IL2Rβ and JAK3 in Human T-cell leukemia virus type 1
(HTLV-1) transformed cell lines and it is believed to aid in the sustained activation of JAK/STAT
[65].
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The JAK/STAT, PI3K/AKT, and RAS/RAF/MEK/ERK pathways are not straightforward
processes. Crosstalk between these pathways complicates their regulation, which means that they
are not simple linear paths, but modify each other’s cascade.
1.5

SIGNIFICANCE AND HYPOTHESIS
Dysregulation of the components of the immune system can result in disease. Proper

activation of the interleukin 2 (IL2) signaling pathway is crucial for regulation of immunity.
Deficiency of IL2 or any of the interleukin 2 receptor (IL2R) components, including IL2Rβ results
in severe autoimmunity mainly due to lack of natural T regulatory cell development [66].
Dysregulation of IL2/IL2R has also been associated to autoimmune diseases. T cells from systemic
lupus erythematosus (SLE) patients show defective IL2 production [67], while CD25+ B cells from
SLE and rheumatoid arthritis (RA) patients show a heightened expression of IL2Rβ [68].
Polymorphisms on the IL2 receptor β have been associated with rheumatoid arthritis, type I
diabetes, Graves disease, multiple sclerosis [69-71], human visceral leishmaniasis [72], and
myasthenia gravis [73]. In addition, IL2Rβ and γ subunits but not IL2 are expressed in the human
papilloma virus-associated cervical cancer cell lines CALO and INBL; they show comparable
phosphorylation of the β subunit by endogenous c-Kit and exogenous IL2, which initiates the
JAK3/STAT5 signaling pathway that drives proliferation or anti-apoptotic signals in these cells
[74]. Thus, such findings point to a possible involvement of IL2R signaling in cervical cancer.
The β subunit of the IL2R is shared with the IL15 receptor complex, which is essential for
natural killer (NK) cell development and survival. No circulating NK cells and abnormalities of T
and B cell function due to downregulation of IL2Rβ were observed in peripheral blood
mononuclear cells (PBMCs) from an infant boy with symptoms of severe combined
immunodeficiency (SCID) [75]. IL15 signaling is needed for proper function and/or development
of macrophages, dendritic cells, monocytes, NK-T cells and intestinal intraepithelial lymphocytes
[76]. Over-expression of IL15 has been linked to several diseases including Celiac disease,
inflammatory bowel diseases, multiple and systemic sclerosis, and rheumatoid arthritis, while its
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deficiency appears to heighten susceptibility to some infectious diseases [76]. Additionally, a
recent study shows that reducing the expression of IL2/IL15Rβ through small interfering RNA
significantly reduced clinical signs of disease in rats with adjuvant-induced arthritis [77]. This
underlines the great potential that IL2Rβ has as a therapeutic target to treat autoimmune diseases.
IL2 and IL15 signaling mediated by the β subunit of the receptor is crucial for homeostasis
of the immune system. The positive regulation of IL2 signaling through tyrosine phosphorylation
of the β subunit has been extensively studied, it allows for recruitment and docking of different
proteins to become tyrosine and serine/threonine phosphorylated. These sites have been mapped
and their effects in signal transduction extensively studied. However, the negative regulation that
might occur through serine and threonine phosphorylation of this receptor has yet to be
characterized. Work from our lab confirmed serine and threonine phosphorylation of IL2Rβ which
has a direct impact on IL2 induced activation of β, JAK3 and STAT5 [56]. Serine and threonine
phosphorylation appear to play an important role in IL2R complex formation and its dysregulation
can disrupt homeostasis of the immune system. Therefore, there is a critical need to characterize
the phosphorylation of serine and threonine sites in order to have a better understanding of the
regulation of the IL2 signaling pathway and its putative role in disease.
The objective of this dissertation is to elucidate novel regulatory mechanisms governing
IL2 signaling through IL2Rβ. The evidence of serine and threonine phosphorylation of IL2Rβ and
its importance for IL2R complex formation is the foundation for the proposed studies. We
hypothesize that phosphorylation of specific serine and threonine residues on IL2Rβ
regulates its signaling capacity and impacts T-cells function. To address this hypothesis, we
first mapped the serine and threonine sites that become phosphorylated on IL2Rβ by using largescale immunoprecipitation coupled to LC-MS/MS. We found thirteen sites to become
phosphorylated in response to IL2 or CA treatment. We choose two sites for characterization: the
proline flanked T450, and S512, which is in close proximity to an important STAT5 binding site.
The generation of phosphospecific antibodies provided a reliable tool to assess the functional role
of the phosphosites as well as the kinase/phosphatase that regulates them. T450 was found to
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become phosphorylated upon induction of IL2 and IL15, which lead us to believe it had a positive
regulatory role in their signal transduction.
The knowledge gathered in this dissertation provides insight into the modulation of IL2
signal transduction through threonine phosphorylation of IL2Rβ. It brings us one step closer to
understanding the fine tune regulation of the IL2 signaling pathway.
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CHAPTER 2
Identification of Novel Serine/Threonine Phosphosites in IL2R
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2.1

INTRODUCTION
IL2 signal transduction is initiated by its engagement to the IL2R, a heterotrimeric complex

consisting of α, β, and γ subunits. Activation of IL2Rβ occurs through the phosphorylation of its
tyrosine residues, which allows for recruitment and docking of proteins like STATs and SHC [20]
and the subsequent activation of downstream signaling molecules involved in proliferation,
survival and apoptosis [3]. Tyrosine phosphorylation of IL2Rβ and its importance on IL2 signal
transduction has been extensively studied. However, the regulation that might occur through serine
and threonine phosphorylation of this receptor has yet to be characterized. Previous work from our
group showed that blocking the serine/threonine phosphatases PP1 and PP2A with CA increases
serine and threonine phosphorylation of IL2Rβ. In addition, CA treatment blocks IL2 induced
tyrosine phosphorylation of β and the association of the IL2R complex [56]. This strongly suggests
that phosphorylation of serine and threonine plays an important role in the activation of IL2Rβ.
Dysregulation of such phosphorylation could disrupt the homeostasis of the immune system.
In order to understand the role of serine and threonine phosphorylation in IL2R we first
sought to identify the residues that become phosphorylated in the receptor under different stimuli.
IL2 has been shown to induce not only tyrosine, but also serine and threonine phosphorylation of
β while CA treatment blocks the serine/threonine phosphatases PP1 and PP2A, allowing for
phosphorylation of such residues [56]. The strategy employed here consisted of
immunoprecipitation coupled to LC-MS/MS analysis. To obtain the  chain in its native
environment we used the NK-like cell line YT, which shows high expression of IL2R [78] and
provided and excellent source of β for large-scale immunoprecipitation, while mass spectrometry
recognizes phosphorylated peptides at a picomol concentration without the need of extensive
purification [79]. A second strategy consisted on overexpression of IL2Rβ via a large-scale
transfection of HEK293 cells with the receptor.
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2.2

MATERIALS AND METHODS

2.2.1 Cell Culture, Transfection and Treatment
The human NK-like cell line YT and the adherent HEK293 cell line were maintained in
RPMI 1640 (Thermo Scientific Inc.) medium with 10% fetal bovine serum (FBS) (Atlanta
Biologicals), 2 mM L-glutamine (Cellgro), and penicillin-streptomycin (50 IU/ml and 50 μg/ml,
respectively) (Cellgro) (complete media) at 37 °C with 5% CO2. YT ells were made quiescent by
growing to exhaustion (> 5X105 cells/mL) and then stimulated with 10,000 IU of human
recombinant IL2 (NCI Preclinical Repository) for 10 minutes, or treated with 100 nM CA (SigmaAldrich) for 15 minutes. Treatments were performed at 37 °C using 20x106 cells per treatment.
Untreated, unstimulated cells were used as control. HEK293 cells were transfected with 36 g of
plasmid pcDNA3.1/GS human IL2R (Invitrogen) per confluent T-150 flask. Cells were harvested
48 h post transfection and were incubated with or without 100 nM CA for 15 minutes. Two
confluent T-150 flasks were used per treatment. Transient transfections of HEK293 cells were
performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
2.2.2 Solubilization of Proteins, Immunoprecipitation, Western Blot and Mass
Spectrometry Analysis
Cells were pelleted and solubilized in lysis buffer (10 mM Tris-HCl (pH 7.6), 5 mM EDTA
(pH 8.0), 50 mM NaCl, 30 mM Na4P2O7, 50 mM NaF, 1 mM Na3VO4 , 1% Triton X-100)
containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 g/ml aprotinin, 2 g/ml leupeptin,
and 1 g/ml pepstatin A, and rotating at 4 °C for 1 h. Whole cell lysates were clarified by
centrifugation (15,000x g, 15 min, 4 °C). For immunoprecipitation reactions, supernatants were
rotated with 3 μg of -IL2Rβ mouse monoclonal antibody clone 561 [80] for 2 hours at 4 °C.
Immune complexes were captured by incubation with Protein A-Sepharose beads (Rockland
Immunochemicals) rotating for 1 h at 4 °C. The beads where then washed three times with ice cold
lysis buffer and eluted by boiling 5 min in 4 x SDS sample buffer (50 mM Tris-HCl (pH 6.8), 100
mM dithiothreitol, 2% SDS, 0.02% promophenol blue, 10% glycerol, pH 6.8). Samples were
resolved in 10% SDS-PAGE and visualized by Coomassie blue staining. Concentration of the
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eluted samples was performed using PTFE membrane centrifugal filter units (Millipore). An
aliquot (5%) of each sample was simultaneously ran in the gel, transferred to polyvinyl-difluoride
(PVDF) membrane and blocked with 1% bovine serum albumin (BSA) for 1 h at room
temperature. Western blot analysis was performed by incubating the membrane with -IL2R
polyclonal antibody C-20 (Santa Cruz Biotechnology) overnight at 4 °C. Assays were developed
with horseradish peroxidase-conjugated goat anti-rabbit IgG (heavy plus light chains; KPL) and
visualized by using enhanced chemiluminescence and x-ray film. Bands corresponding to IL2R
were excised from Coomassie blue stained gel and sent to the Taplin Biological Mass
Spectrometry Facility (Harvard University) analysis through liquid chromatography-tandem mass
spectrometry (LC-MS/MS). Any protein with three or more unique peptide matches was
considered confidently identified. Manual examination of the spectra as well as the probabilitybased score Ascore where used to determine phosphorylation site localization [81].
2.3

RESULTS

2.3.1 Large-scale Immunoprecipitation of IL2R and Phosphosite Mapping
Transmembrane proteins have proven to be difficult to study due to their low abundance
biological membranes. To circumvent this, a large-scale immunoprecipitation of the receptor was
performed to obtain the concentration of IL2R required for LC-MS/MS analysis. For each
sample, 109 YT cells per treatment were used for immunoprecipitation of . Cells were left
untreated, stimulated with IL2 for 10 min or treated with CA for 15 min. IL2R was
immunoprecipitated and the samples separated by 10% SDS-PAGE and visualized by Coomassie
blue staining (Fig. 2.1A). A small aliquot of the sample (5%) was analyzed by Western blot for
tyrosine phosphorylation and total IL2R (Fig. 2.1B) to ensure IL2 induced activation of the
receptor. IL2 stimulation induced tyrosine phosphorylation of the receptor. In addition, a reduction
in IL2R mobility was observed in the sample stimulated with IL2 as well as the CA treated
sample, a phenomenon frequently observed in phosphorylated proteins [56]. Representative data
of several experiments is shown. The bands corresponding to non-stimulated (75-KDa), IL225

stimulated (80-KDa), and CA-treated (100-KDa) IL2R were excised, subjected to trypsin and
Asp-N digestion, and analyzed by liquid chromatography-tandem mass spectrometry. YT Spectra
analysis using the Sequest search algorithm revealed a combined protein coverage of 61% for the
non-treated sample, 84% for IL2 stimulated, and 99% for CA treated cells, and the identification
of several novel IL2R phosphorylated peptides. In an attempt to confirm the results in a different
system, a large-scale transfection of HEK293 with IL2R was performed as indicated in the
Methods section. Cells were left untreated or incubated with CA for 15 minutes. IL2R was
immunoprecipitated and the samples processed and analyzed as described for YT cells. The protein
coverage was 90% for the untreated sample and 85% for the CA treatment. Several
phosphorylation sites were also identified with this strategy. The location of the novel
phosphorylation sites in the receptor is shown in (Fig. 2.1C). The diagram includes the novel
phosphorylation sites found in the present study as well as residues previously reported to be
phosphorylated and important binding sites for signal transduction. Table 2.1 shows a summary of
treatments, coverage, and phosphosites identified employing each of the two strategies.
2.3.2 Mass Spectra and Conservation of Two Novel Phosphorylation Sites Selected for
Characterization
The strategy employed in section 2.3.1 lead to the identification of 13 residues that become
phosphorylated in the cytoplasmic domain of IL2R. The tyrosine residues Y355, Y392 and Y510
were identified in this study and have already been characterized [82]. Ten serine and threonine
residues were also identified as phosphosites, five of which have been previously reported in the
literature, however, their identification was through proteomic analysis, meaning that no site
specific methods were employed in order to characterize them [83]. Here we report S268, T394,
T450, S484, and S512 as novel IL2Rphosphorylation sites. Of special interest were T450 and
S512.
Threonine-450 was found to be phosporylated in most of our samples. In addition, it is a
proline-flanked threonine and the PPTP motif is a known ERK1 and ERK2 substrate [84]. Tandem
mass spectrum for the peptide DWDPQPLGPPTPGVPDVDFQPPPELVLR, which contains the
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phosphorylated IL2R T450 residue (underlined) from IL2 stimulated samples, is shown in Fig.
2.2A. This phospho-threonine was identified in YT cells that were untreated, IL2 stimulated, and
CA treated. In addition, this site was identified in IL2R of transfected HEK293 cells treated with
CA. Comparable spectra was obtained for the peptide containing T450 from the all the samples
(data not shown). To determine the extent of T450 conservation, human IL2R protein sequence
was aligned with IL2 receptor beta from other species. T450 as well as the surrounding amino acid
sequence was found to be well conserved among eight different species, mainly primates, and was
found to be replaced by a serine in mice (Fig. 2.2B). Data suggests that phosphorylation of T450
could be a result of an evolutionary recent gain-of-function mutation related to a specialized
activity of the more complex immune system in higher organisms.
The second site of interest S512 was found to be phosphorylated in IL2R from CA treated
YT cells. This phosphosite is in close proximity to Y510, an important STAT5 binding site. Serine
512 is localized in a SLQE motif, a known CK2 substrate [85]. Tandem mass spectrum for the
peptide DAYLSLQELQGQDPTHLV, which contains the phosphorylated IL2R S512 residue
(underlined) from CA treated samples, is shown in Fig. 2.3A. To determine the extent of S512
conservation among different species, human IL2R protein sequence was aligned with IL2
receptor beta from other species. S512 as well as the surrounding amino acid sequence was found
to be well conserved among thirteen different species, including primates, bovine, marsupials and
mouse (Fig. 2.3B).
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Figure 2.1: Identification and mapping of novel phosphorylation sites in human IL2R.
YT cells were left untreated (-), stimulated with IL2 for 10 min (+) or treated with CA (100
nM) for 15 min. Cell lysates were immunoprecipitated (IP) with -IL2R and separated by
SDS-PAGE. One set was Coomassie blue-stained (A), and the other was immunoblotted (IB)
(B) with -phospho-Tyr (-pY), or -IL2R antibodies. HC, heavy chain; LC, light chain. C,
Cytoplasmic domain architecture of human IL2R. Tyrosines identified in the present study
are in green. Serine and threonine phosphorylation sites are in red and the amino acid sequence
surrounding the residue is indicated. Novel serine/threonine sites are designated with an
asterisk. Numbers indicate amino acid residues of human IL2R. The binding sites for JAK1,
JAK3, STAT5 and SHC are shown.
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Table 2.1: LC-MS/MS identification of phosphorylation sites in IL2R.
Treatment

YT

HEK293

Coverage

Phospho residues

Coverage

Phospho residues

None

61%

-

90%

T256, S267, S268

IL2

84%

S405, T450, Y355,
Y392, Y510

-

-

CA

99%

T308, T394, S432,
T450, S484, S512

85%

T256, S267, S268, T394,
S432, T450, S484
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Figure 2.2: Tandem mass spectra and sequence conservation of IL2R T450. A, tandem mass spectra
of a monophosphorylated peptide showing site localization of T450 on IL2 stimulated YT cells,
as indicated by asterisks. B, amino acid sequence alignment of the region surrounding T450
(asterisk) from different organisms using CLUSTAL OMEGA program.
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Figure 2.3: Tandem mass spectra and sequence conservation of IL2R S512. A, tandem mass spectra
of a monophosphorylated peptide showing site localization of S512 on CA treated YT cells,
as indicated by asterisks. B, amino acid sequence alignment of the region surrounding S512
(asterisk) from different organisms using CLUSTAL OMEGA.
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2.4

DISCUSSION
In an effort to gain insight into the complex regulation of IL2 signaling at the receptor

level, mapping of serine and threonine phosphorylation sites on IL2R was pursued. The strategy
of large-scale immunoprecipitation of  followed by identification of phosphopeptides through
LC-MS/MS revealed thirteen sites to be differentially phosphorylated in IL2R in response to
diverse stimuli (Figures 2.1, 2.2, 2.3 and Table 2.1). These findings provide insight into the
putative role for serine and threonine phosphorylation for IL2 signaling.
Phosphorylation of proteins is a major post-translational modification employed by cells
for transmitting signals. It can alter a protein’s cellular localization and substrate binding affinity
and regulate processes like differentiation, proliferation and cell cycle. For example, engagement
of IL2 to its receptor results in the recruitment and activation of the protein tyrosine kinases JAK1
and JAK3, which phosphorylate each other and specific tyrosines in the cytoplasmic domain of
the receptor providing docking sites for SH2 domain containing proteins like SHC and STATs. In
this way initiation of several signaling pathways including JAK/STAT, PI3K, and MEK/ERK
occurs [3]. The general focus of study has been the positive regulation of signaling through tyrosine
phosphorylation of proteins, which was regarded as an “ON/OFF” switch for activation. However,
the importance of serine and threonine phosphorylation in cytokine signaling has been recently
highlighted. Several proteins involved in IL2 signaling become not only tyrosine, but also serine
and threonine phosphorylated. One example is STAT5, which requires not only tyrosine, but also
serine phosphorylation of specific residues for maximum transcriptional activation [86]. In
addition, CA induced serine/threonine phosphorylation has been shown to regulate IL2 signaling
at multiple levels, including formation of the receptor complex and activation of downstream
signaling molecules [56].
We were able to successfully identify several phosphorylated residues in the cytoplasmic
domain of IL2R in response to different stimuli. Through phosphoamino acid analysis, our group
had reported that IL2R becomes not only tyrosine, but also serine and threonine phosphorylated
in response to IL2. In addition, inhibition PP2A heightened serine and threonine phosphorylation
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and diminished IL2 induced tyrosine phosphorylation of the  chain of the receptor [56]. Here
S405 and T450 were identified to become phosphorylated in response to IL2 stimulation. In
addition, serines 267, 268, 432, 484, and 512 as well as threonine 256, 308, 394 and 450 were
found to be phosphorylated following CA treatment. Threonine 450 and serine 512 were not
previously characterized and were chosen for further examination. Amino acid sequence alignment
of the region surrounding each of the phosphosites from different organisms revealed conservation
among different species. Interestingly, S512 was found to be more highly conserved than T450.
In conclusion, using immunoprecipitation coupled to mass spectrometry five novel
phosphosites in IL2R were identified. In order to elucidate the potential regulatory role of the
IL2 induced T450 and the CA induced S512 in IL2 signaling, phospho-specific polyclonal
antibodies were generated against those phosphoresidues. The characterization of such antibodies
is the focus of the next chapter.
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CHAPTER 3
Characterization of -T450 and -S512 IL2R Antibodies
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3.1

INTRODUCTION
Serine and threonine phosphorylation of proteins has been proven to be a key player in the

regulation of signaling. According to our investigation, IL2R T450 becomes phosphorylated in
response to IL2. In addition, CA induced inhibition of phosphatases results in phosphorylation of
S512. In order to verify phosphorylation of T450 and S512 in IL2R and to elucidate their role in
IL2 signaling, we developed phosphospecific polyclonal antibodies against those sites. This
chapter is focused on the characterization of the -pT450 and -pS512 IL2R antibodies by testing
their efficacy through ELISA, specificity through dot blot analysis and peptide competition assays,
functional affinity through surface plasmon resonance (SPR), and application through
immunoprecipitation of protein as well as total cell lysates testing through western blot. These
antibodies represent new tools that will help to more precisely define the function of T450 and
S512 phosphorylation.
3.2

MATERIALS AND METHODS

3.2.1 Generation of Phosphospecific Antibodies
The -pT450 IL2R rabbit polyclonal antibody was custom-generated by GenScript
(Piscataway, NJ) using the immunogen LGPP(pT)PGVPDLVDFC (where pT indicates phosphothreonine) coupled to keyhole limpet hemocyanin. The -pS512 IL2R rabbit polyclonal antibody
was generated using the immunogen DAYL(pS)LQELQGQDPC in a similar fashion. Four rabbits
were immunized per phosphopeptide. Efficacy of serum from final bleeds was tested through
enzyme-linked immunosorbent assay (ELISA) by the company. According to their protocol, wells
were coated with 100 l of either phosphopeptide or non-phosphopeptide at 4 g/ml. Peroxidase
conjugated -rabbit IgG (H&L) goat antibody was used as the secondary antibody.
3.2.2 Surface Plasmon Resonance
In vitro studies to determine the functional affinity between phosphopeptide or nonphosphopeptide and either pT450 IL2R or pS512 IL2R anti-serum were performed on a Biacore
T100 instrument (GE Healthcare). Phosphopeptide LGPP(pT)PGVPDLVDFC and non35

phosphopeptide

LGPPTPGVPDLVDFC

(T450)

as

well

as

phosphopeptide

DAYL(pS)LQELQGQDPC and non-phosphopeptide DAYLSLQELQGQDPC (S512), were
modified with PDEA and covalently linked to a carboxymethylated dextran (CM5) sensor chip via
surface thiol immobilization. Aqueous solution of the analytes (pT450 or pS512 IL2R anti-sera)
at different dilutions (1:10, 1:20, 1:40, 1:100, 1:200, 1:400 and 1:1000) were injected through the
flow cells at 30μl/min for 600 seconds at 25 °C. Dissociation was allowed for 600 seconds and
regeneration was performed with 50 mM NaOH for 360 seconds at a flow rate of 30 L/min.
Kinetic data was analyzed using the Biacore evaluation software. To determine the binding
kinetics of the serum to the peptides, a bivalent analyte model was used. Functional affinity was
determined using a 1:1 steady state model.
3.2.3 Dot Blot Analysis and Peptide Competition
Phosphopeptides and non-phosphopeptides were diluted in water and blotted in decreasing
concentration (1000 ng, 100 ng, 10 ng, 1 ng, and 0.1 ng) into methanol activated PVDF
membranes. The membranes were allowed to dry, re-activated and then blocked in 1% BSA 1 h at
room temperature followed by incubation with phosphospecific antibodies. Peptide competition
assay was performed by incubating the phosphospecific antibodies with increasing concentrations
(0.1 g, 1 g, 10 g, and 50 g) of either the phosphopeptide or the non-phosphopeptide for 2 h
rotating at room temperature before probing dot blotted membranes.
3.2.4 Cell Culture, Transfection and Treatment
The human HEK293 cell line was maintained as described in section 2.2.1. Cells were
grown to 90% confluency in a 6-well plate and transfected with 1 g of plasmid pcDNA3.1/GS
human IL2R (Invitrogen). Cells were harvested 48 h post transfection and were incubated with
or without 100 nM CA for 1 h at 37 °C. Transient transfections of HEK293 cells were performed
with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
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3.2.5 Solubilization of Proteins, Immunoprecipitation and Western blot analysis
Cells were pelleted, solubilized, and clarified as described in section 2.2.2. For
immunoprecipitation reactions, supernatants were rotated with 3 μg of -IL2Rβ mouse
monoclonal antibody clone 561 [80] for 2 hours at 4 °C. Immune complexes were captured by
incubation with Protein A-Sepharose beads (Rockland Immunochemicals) rotating for 1 h at 4 °C.
The beads where then washed three times with ice cold lysis buffer and eluted by boiling 5 min in
2 x SDS sample buffer (50 mM Tris-HCl (pH 6.8), 100 mM dithiothreitol, 2% SDS, 0.02%
promophenol blue, 10% glycerol, pH 6.8). Samples were resolved in 10% SDS-PAGE, transferred
to polyvinyl-difluoride (PVDF) membrane and blocked with 1% bovine serum albumin (BSA) for
1 h at room temperature. Western blot analysis was performed by incubating the membrane with
the custom generated -pT450 IL2R rabbit polyclonal antibody 2 h at room temperature. Assays
were developed with horseradish peroxidase-conjugated goat anti-rabbit IgG (heavy plus light
chains; KPL) and visualized by using enhanced chemiluminescence and x-ray film. For reblotting,
polyvinylidene difluoride membranes were incubated with stripping buffer (100 mM mecaptoethanol, 2% SDS, 62.5 mM Tris-HCL, pH 6.7) at 55 °C for 30 min, blocked, and then
reprobed with -IL2R C-20 (Santa Cruz Biotechnology) rabbit polyclonal antibody overnight at
4 °C.
3.3

RESULTS

3.3.1 -pT450 IL2R Antiserum Preferentially Recognizes Phosphorylated Peptide
Phosphorylation of T450 on IL2R was identified through mass spectrometry analysis and
may represent a novel mechanism of regulation of IL2 signaling. To verify that IL2R is
phosphorylated at threonine 450 and to investigate the regulatory role of this phosphorylation site,
a phospho-specific polyclonal antibody was generated. Four rabbits were immunized with the
phosphopeptides and are represented by the numbers 9843, 9844, 9845, and 9846. Final bleed
antisera were analyzed by ELISA and specificity to phosphopeptide (blue) versus nonphosphopeptide (red) was confirmed for all four rabbits (Fig 3.1).
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The affinity of 9846 antisera to the phosphopeptide versus the non-phosphopeptide was
further tested by SPR. As shown in figure 3.2, the highest pre-concentration of both the
phosphopeptide and non-phosphopeptide on the CM5 chip was obtained using a pH 4 buffer.
Similar amount of ligands (phosphopeptide and non-phosphopeptide) were immobilized on the
dextran surface (Table 3.1). Increasing dilutions of the antiserum were tested for binding response
to the immobilized phosphopeptide and non-phosphopeptide. The concentration of the antibody
was assigned to 10 g/mL on the Biacore, however, for the purpose of this assay the values are
represented as arbitrary units. Binding curves show higher response (resonance units) for the
phosphopeptide versus the non-phosphopeptide for all the dilutions tested (Fig 3.3). In addition,
dissociation of the antiserum occurs more rapidly from the non-phosphopeptide versus the
phosphopeptide. Binding kinetics was determined using a bivalent analyte model. Expected values
are shown in black and obtained values are in red. We observed a higher association rate constant
of the antiserum to the phosphopeptide versus the non-phosphopeptide. In addition, the
dissociation rate constant of the antiserum from the phosphopeptide was about half of that for the
non-phosphopeptide (Fig. 3.4). The functional affinity of the antibody was tested by using a 1:1
steady state model and the dissociation equilibrium constant (KD) of the antiserum was 105 nM
for the phosphopeptide and 596 nM for the non-phosphopeptide (Fig. 3.5). Representative data
from three independent experiments are shown. Statistical significance was determined using
Student’s t test (*, p < 0.05; **, p < 0.01) and the difference in association, dissociation and
equilibrium constants between the phosphopeptide and non-phosphopeptide were found to be
statistically significant.
To determine whether the IL2Rphospho-specific antibody cross-reacts with the nonphosphorylated form of the peptide, dot blot analysis with the immunizing phospho-peptide and
the corresponding non-phosphorylated peptide was performed (see section 3.2.1 for sequences).
Increasing amounts of pT450 or T450 peptides were spotted on to PVDF membranes and
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Figure 3.1: pT450 IL2R antisera has specificity towards phosphopeptide. Four rabbits,
9843, 9844, 9845, and 9846, were immunized with the phosphopeptide. Increasing dilutions of
each antiserum were analyzed through ELISA. Specificity of the antisera to phosphopeptide
(blue) and non-phosphopeptide (red) is shown.
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Figure 3.2: Phosphopeptide and non-phosphopeptide for immobilization. Scouting for
immobilization of pT450 (top) and T450 (bottom) was performed by pre-concentrating the
phosphopeptide or the non-phosphopeptide on the dextran surface of the CM5 chip using 10
mM Acetate buffer at pH 4 (red), 4.5 (green), 5 (blue), and 5.5 (pink).
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Table 3.1: Similar levels of phospho T450 and non-phospho T450 were immobilized for SPR
analysis. Phosphopeptide and non-phosphopeptide were immobilized on the dextran surface of
the CM5 chip using 10 mM Acetate buffer at pH 4. Flow cells 1 and 3 were used as controls. Nonphosphopeptide was immobilized on flow cell 2 while the phosphopeptide was immobilized on
flow cell 4.
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Phospho T450

45

Non-phospho T450

Figure 3.3: IL2R pT450 antiserum shows higher binding response to phosphopeptide
versus non-phosphopeptide. Increasing dilutions (purple 1:10, grey 1:20, yellow 1:40, aqua
1:100, pink 1:200, blue 1:400, green 1:1000 and red blank) of the antiserum were tested for
binding response to the immobilized phosphopeptide and non-phosphopeptide. Samples were
injected for 600 seconds and then allowed to dissociate for 600 seconds.
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Figure 3.4: IL2R pT450 antiserum binding kinetics. Binding kinetics was determined
using a bivalent analyte model. Expected (black) and obtained (red) values are shown along
with the association and dissociation rate constants.
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PhosphoT450

KD(nM) Rmax(RU) Chi²(RU²)
105
2260.4
1810

Non-phosphoT450

KD(nM) Rmax(RU) Chi²(RU²)
596
1961.3
281

t-test
Ka
Kd
KD
0.0070725 0.018467054 0.009166

Ka
Kd
KD
Phospho T450 4586 ± 275.57*
1.926E-4 ± 7.793E-5** 1.147E-7 ± 8.737E-9**
Non-phospho T450 2228.33 ± 144.58 5.377E-4 ± 2.225E-5
5.173E-7 ± 6.827E-8
* p < 0.05 ** p < 0.01

Figure 3.5: IL2R pT450 antiserum functional affinity to phosphopeptide. The functional
affinity of the antibody was tested by using a 1:1 steady state model. Dissociation equilibrium
constant (KD) of the antiserum to the phosphopeptide and non-phosphopeptide is shown.
Statistical significance was determined using Student’s t test (*, p < 0.05; **, p < 0.01) using
data from three experiments and the difference in association, dissociation and equilibrium
constants between the phosphopeptide and non-phosphopeptide were found to be statistically
significant.
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immunoblotted with -pT450 IL2R at 1:5000 and 1:10000 dilutions. For both concentrations,
the -pT450 IL2R antibody primarily recognized the phosphorylated peptide but not its nonphosphorylated counterpart, indicating that this phospho-specific antibody does not cross-react
significantly with the non-phosporylated peptide (Fig. 3.6 top panel). In addition, a peptide
competition assay was performed to confirm specificity of the antibody. Dot blotted membranes
were probed using -pT450 IL2R pre-incubated with increasing amounts of the nonphosphopeptide or phosphopeptide as indicated. The -pT450 IL2R phospho-antibody was
specifically blocked by the phospho-, but not the non-phosphopeptide in a dose-dependent manner
(Fig. 3.6, middle and bottom panel).
To further characterize this phospho-specific antibody, HEK293 cells were transfected
with cDNA encoding WT IL2R, T450A or T450E mutants. 48 hrs post-transfection cells were
treated with 100 nM CA for 1 h and IL2R immunoprecipitated, resolved in SDS-PAGE,
transferred to PVDF membrane and examined for phosphorylation of T450 by Western blot. As
shown if Fig. 3.7, the -pT450 IL2R antibody recognizes CA treated WT IL2R but not the
T450A mutant. The level of recognition of the T450E mutant by the antibody was comparable to
non-treated WT, however, CA induced phosphorylation signal is lost on both mutants. Reprobing
these blots with -IL2R antibody confirmed similar IL2R expression. This data confirms the
specificity of our phospho-specific antibody towards the T450 phosphorylated form of IL2R in
Western blot analysis.
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Figure 3.6: IL2R pT450 recognizes phosphorylated peptide and is specific. Antibodies
were tested by dot blot analysis using decreasing concentrations of IL2R T450 and pT450
peptides spotted on to PVDF membranes and incubated with two different dilutions of the antiserum as indicated (top panel). For peptide competition analysis, the polyclonal pT450 IL2R
antibody was pre-blocked for 2 h at room temperature with increasing concentrations of the
non-phosphopeptide or phosphopeptide as indicated (middle and bottom panel).
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Figure 3.7: Anti-IL2R pT450 antibody recognizes CA treated WT IL2R. HEK293 cells
were transfected with plasmids for WT IL2R, T450A or T450E mutants. At 48 h posttransfection cells were incubated in the absence of presence of CA (100 nM) for 60 min.
IL2R was immunoprecipitated (IP), separated by SDS-PAGE, and immunoblotted (IB) with
-pT450 IL2R. Membrane was stripped and reprobed with -IL2R
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3.3.2 -pS512 IL2R Antiserum Preferentially Recognizes Phosphorylated Peptide
Phosphorylation of S512 on IL2R was identified through mass spectrometry analysis and
may represent a novel mechanism of regulation of IL2 signaling. To verify that IL2R is
phosphorylated at threonine S512 and to investigate the regulatory role of this phosphorylation
site, a phospho-specific polyclonal antibody was generated. Four rabbits were immunized with the
phosphopeptides and are represented by the numbers 9817, 9818, 9819, and 9820. Final bleed
antisera were analyzed by ELISA and limited specificity to phosphopeptide (blue) versus nonphosphopeptide (red) was observed for all four rabbits (Fig 3.8).
The affinity of 9818 antisera to the phosphopeptide versus the non-phosphopeptide was
further tested by SPR. As shown in figure 3.9, the highest pre-concentration of both the
phosphopeptide and non-phosphopeptide on the CM5 chip was obtained using a pH 4 buffer.
Similar amount of ligands (phosphopeptide and non-phosphopeptide) were immobilized on the
dextran surface (Table 3.3). Increasing dilutions of the antiserum were tested for binding response
to the immobilized phosphopeptide and non-phosphopeptide. The concentration of the antibody
was assigned to 10 g/mL on the Biacore, however, for the purpose of this assay the values are
represented as arbitrary units. Binding curves show higher response (resonance units) for the
phosphopeptide versus the non-phosphopeptide for all the dilutions tested (Fig 3.10). In addition,
dissociation of the antiserum occurs more rapidly from the non-phosphopeptide versus the
phosphopeptide. Binding kinetics was determined using a bivalent analyte model. Expected values
are shown in black and obtained values are in red. We observed a higher association rate constant
of the antiserum to the phosphopeptide versus the non-phosphopeptide. In addition, the
dissociation rate constant of the antiserum from the phosphopeptide was 3 log smaller than that
for the non-phosphopeptide (Fig. 3.11). The functional affinity of the antibody was tested using a
1:1 steady state model and the dissociation equilibrium constant (KD) of the antiserum was found
to be 162.3 nM for the phosphopeptide and 424.4 nM for the non-phosphopeptide (Fig. 3.12).
Respresentative data from three independent experiments are shown. A t-test was performed and
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Figure 3.8: pS512 IL2R antisera shows limited specificity towards phosphopeptide. Four
rabbits represented by the numbers 9817, 9818, 9819, and 9820, were immunized with the
phosphopeptides. Increasing dilutions of each antiserum were analyzed through ELISA.
Specificity of the antisera to phosphopeptide (blue) and non-phosphopeptide (red) is shown.
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Figure 3.9: Phosphopeptide and non-phosphopeptide for immobilization. Scouting for
immobilization of pS512 and S512 was performed by pre-concentrating the phosphopeptide or
the non-phosphopeptide on the dextran surface of the CM5 chip using 10 mM Acetate buffer at
pH 4 (red), 4.5 (green), 5 (blue), and 5.5(pink).
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Flow Cell

Ligand

Response Bound (RU)

1
2
3
4

IL2R S512
IL2R pS512

209.5
159.3

Table 3.2: Similar levels of phospho S512 and non-phospho S512 were immobilized for
SPR analysis. Phosphopeptide and non-phosphopeptide were immobilized on the dextran
surface of the CM5 chip using 10 mM Acetate buffer at pH 4. Flow cells 1 and 3 were used
as controls. Non-phosphopeptide was immobilized on flow cell 2 while the phosphopeptide
was immobilized on flow cell 4.
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Figure 3.10: IL2R pS512 antiserum indicates higher binding response to phosphopeptide
versus non-phosphopeptide. Increasing dilutions (green 1:5, purple 1:10, grey 1:20, yellow 1:40,
aqua 1:100, pink 1:200, blue 1:400, dark green 1:1000, and red blank) of antiserum were tested for
binding response to the immobilized phosphopeptide and non-phosphopeptide. Samples were
injected for 600 seconds and then allowed to dissociate for 600 seconds.
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Figure 3.11: IL2R pS512 antiserum binding kinetics. Binding kinetics was determined
using a bivalent analyte model. Expected (black) and obtained (red) values are shown along
with the association and dissociation rate constants.
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Phospho S512

KD(nM) Rmax(RU) Chi²(RU²)
162.3
1542.2
717

Non-phospho S512

KD(nM)
424.4

t-test
Ka
Kd
KD
0.0015816 0.002446251 0.098355

Rmax(RU) Chi²(RU²)
827.7
98.5

Ka
Kd
KD
Phospho S512 3955 ± 399.7** 7.991E-6 ± 8.5E-6** 1.713E-7 ± 8.238E-9
Non-phospho S5123262 ± 391.8
1.285E-3 ± 1.068E-4 4.35E-7 ± 1.468E-7
* p < 0.05 ** p < 0.01

Figure 3.12: IL2R pS512 antiserum functional affinity to phosphopeptide. The functional
affinity of the antibody was tested by using a 1:1 steady state model. Dissociation equilibrium
constant (KD) of the antiserum to the phosphopeptide and non-phosphopeptide is shown.
Statistical significance was determined using Student’s t test (*, p < 0.05; **, p < 0.01) using
data from three experiments and the difference in association and dissociation constants
between the phosphopeptide and non-phosphopeptide were found to be statistically significant.
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the difference in association, dissociation and equilibrium constants between the phosphopeptide
and non-phosphopeptide were found to be statistically significant (Table 3.2).
To determine whether the S512 IL2Rphospho-specific antibody cross-reacts with the
non-phosphorylated form of the peptide, dot blot analysis with the immunizing phospho-peptide
and the corresponding non-phosphorylated peptide was performed (see section 3.2.1 for
sequences). Increasing amounts of pS512 or S512 peptides were spotted on to PVDF membranes
and immunoblotted with -pS512 IL2R at 1:5000 and 1:10000 dilutions. For both concentrations,
the -pS512 IL2R antibody primarily recognized the phosphorylated peptide but not its nonphosphorylated counterpart, indicating that this phospho-specific antibody does not cross-react
significantly with the non-phosporylated peptide (Fig. 3.13, top panel). In addition, a peptide
competition assay was performed to confirm specificity of the antibody. Dot blotted membranes
were probed using -pS512 IL2R pre-incubated with increasing amounts of the nonphosphopeptide or phosphopeptide as indicated. The -pS512 IL2R phospho-antibody was
specifically blocked by the phospho-, but not the non-phosphopeptide in a dose-dependent manner
(Fig. 3.13, middle and bottom panel).
To further characterize this phospho-specific antibody, YT cells (20x106) were treated with
100 nM CA for 15 min and IL2R immunoprecipitated, resolved in SDS-PAGE, transferred to
PVDF membrane and examined for phosphorylation of S512 by Western blotting. As shown if
Fig. 3.14 (top panel), the -pS512 IL2R antibody recognizes IL2R from CA treated but
not from the non-treated cells. Reprobing these blots with -IL2R antibody confirmed similar
IL2R expression. In a similar fashion, YT cells were stimulated with IL2, treated with CA or OA,
or left untreated and IL2R immunoprecipitated and samples analyzed by Western blot using
antibody previously blocked with phosphopeptides or cleared with peptide. Results show that the
9818 antibody recognizes IL2R from CA and OA treated cells. However when the antibody is
pre-incubated with the phosphopeptide, the signal is lost (Fig. 3.14, bottom panel). This data
confirms the specificity of our phospho-specific antibody towards the S512 phosphorylated form
of IL2R in Western blot analysis.
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Figure 3.13: IL2R pS512 recognizes phosphorylated peptide and is specific. Antibodies were
tested by dot blot analysis using decreasing concentrations of IL2R S512 and pS512 peptides
spotted on to PVDF membranes and incubated with two different dilutions of the anti-serum as
indicated (top panel). For peptide competition analysis, the polyclonal pS512 IL2R antibody was
pre-blocked for 2 h at room temperature with increasing concentrations of the non-phosphopeptide
or phosphopeptide as indicated (middle and bottom panel).
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Figure 3.14: IL2R pS512 antibody 9818 recognizes IL2R from CA and OA treated YT
cells and the signal is blocked by the phospho- but not the non-phosphopeptide. YT cells
were incubated with or without CA (100 nM) for 15 min at 37 °C. IL2R was
immunoprecipitated (IP), separated by SDS-PAGE, and Western blotted (WB) as indicated
(upper panel). For the peptide competition assay (lower panel), cells were left untreated,
stimulated with IL2 (103 IU, 5 min), treated with CA (100 nM, 15 min) or OA (250 nM, 1 h).
IL2R was immunoprecipitated (IP) and samples were analyzed through Western blot using
pS512 IL2R antibody 9818 previously incubated with 10 g of either the phosphopeptide or
the non-phosphopeptide.
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3.4

DISCUSSION

In order to study the importance of the two novel IL2R phosphorylation sites identified through
mass spectrometry T450 and S512, rabbit polyclonal phosphospecific antibodies were generated.
The strategy for characterization of the antibodies which included ELISA, SPR, dot blot, and
Western blot of immunoprecipitated IL2Rβ revealed specificity of our antibodies to be used in
Western blot analysis of both immunoprecipitated proteins and total cell lysates. Both -pT450
and -pS512 IL2R antisera preferentially recognized their corresponding phosphorylated
peptide; displayed higher binding response, stronger binding kinetics and functional affinity, they
were also specifically blocked by the phospho- but not non-phosphopeptide. In addition, the IL2R pT450 antibody recognized CA treated WT IL2R but not the phosphodeletion mutant
T450A. Both -pT450 and -pS512 IL2R proved to be useful for Western blot analysis of
immunoprecipitated protein and total cell lysates.
These findings support the use of phosphospecific antibodies as reliable new tools for
investigating the functional role of T450 and S512 in IL2 receptor signal transduction, its
mechanism of phosphorylation and dephosphorylation.
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CHAPTER 4
IL2R T450 is a Novel IL2 and IL15 Induced Phosphosite
Regulated by ERK1/2 and PP1
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4.1

INTRODUCTION
IL2 and IL15 share the β and γc subunits of their receptors and utilize JAK/STAT molecules

for signaling. The result is an overlap of some cellular functions since both cytokines induce the
proliferation of B and T cells and the generation of cytotoxic T lymphocytes and NK cells.
However, IL2 and IL15 also play distinct roles necessary for homeostasis of the immune system.
The primary function of IL2 is both the expansion and elimination of self-reactive T-cells while
IL15 supports the survival of memory T-cells [87]. Activation of IL2Rβ by IL2 and IL15 occurs
through JAK mediated phosphorylation of its tyrosine residues, which allows for recruitment and
docking of proteins like STATs and SHC [20] and the subsequent activation of downstream
signaling molecules involved in cell proliferation, survival and apoptosis [3].

Through

phosphoamino acid analysis, our group has shown threonine phosphorylation of the receptor in
response to IL2 [56], although the specific regulatory role it might play on signaling remains to be
elucidated. The focus of this chapter was to determine wether IL2Rβ is phosphorylated at T450 in
response to physiological stimuli. Several human malignant hematopoietic cell lines along with
non-tumorigenic primary lymphocytes were stimulated with IL2 or IL15 and phosphorylation of
T450 assessed by Western blot using the -pT450 IL2R antibody. In addition, using
kinase/phosphatase inhibitors along with siRNA and purified phosphatases, we investigated the
kinases and phosphatases involved in mediating such phosphorylation/dephosphorylation events.
We provide evidence that T450 phosphorylation is mediated by ERK1/2 in response to IL2 and
IL15 and dephosphorylated by PP1.

4.2

MATERIALS AND METHODS

4.2.1 Cell Culture and Treatment
The human YT, KIT225, HUT102, HH, MT2, and SUPT1 cell lines were maintained in
RPMI 1640 medium containing 10% fetal bovine serum (Atlanta Biologicals), 2 mM L-glutamine,
and penicillin-streptomycin (50 mg/ml) (complete RPMI). KIT225 cells were supplemented with
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100 IU/ml human recombinant IL2 (NCI Preclinical Repository). Human peripheral blood
mononuclear cells (PBMCs) from healthy donors (Research Blood Components) were purified by
isocentrifugation (Ficoll-Hypaque), and activated with phytohemagglutinin (PHA) (10 µg/ml) for
72 h as previously described [88]. Quiescent PBMCs or malignant hematopoietic cell lines were
stimulated with human recombinant IL2 (103 IU) or human recombinant IL15 (0.49 µg/ml) (NCI
Preclinical Repository) at 37 °C for the indicated times. Kinase and phosphatase inhibition studies
with wortmannin (Calbiochem), KT5720 (Sigma), tofacitinib and trametinib (Selleck Chemicals),
okadaic acid (OA; Millipore), tautomycin (TAU; Santa Cruz), cyclosporin A (CSA; Sigma) and
ERK Inhibitor II – FR180204 (Santa Cruz) were performed for 1 h while calyculin A (CA;
Invitrogen) treatment was performed for 15 minutes at 37 °C at the indicated concentrations.
4.2.2 Solubilization of Proteins, Immunoprecipitation, and Western Blot Analysis
Cells were pelleted, lysed and subjected to immunprecipitation and Western blot analysis
as previously reported [89]. For all samples, total protein was determined by the bicinchoninic acid
method (Pierce). Western blot assays were developed with horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin G (IgG; heavy plus light chains) or goat anti-rabbit IgG (heavy plus
light chains; KPL) and visualized by using enhanced chemiluminescence and X-ray film. For
reblotting, polyvinylidene difluoride membranes were incubated with stripping buffer (100 mM
β-mecaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) at 55 °C for 30 min, blocked, and then
reprobed. The anti-phosphothreonine 450 (α-pT450) IL2Rβ rabbit polyclonal antibody was
custom-generated

by

GenScript

(Piscataway,

NJ)

using

the

immunogen

LGPP(pT)PGVPDLVDFC (where pT indicates phospho-threonine) coupled to keyhole limpet
hemocyanin. The anti-JAK3 [90] antibody was used as previously described. A monoclonal mouse
antibody made against the IL2Rβ chain (561-IgG2,) was a generous gift from Dr. Richard Robb
[91]. The anti-phospho-Tyr694 STAT5a and Tyr699 STAT5b (pYSTAT5) monoclonal antibody,
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anti-STAT5 polyclonal antibody, anti-phospho-p44/42 MAPK (ERK1/2) Thr202/Tyr204 polyclonal
antibody and anti- p44/42 MAPK (ERK1/2) polyclonal antibody were purchased from Cell
Signaling Technology and were used according to the manufacturer’s protocol along with antiphosphotyrosine monoclonal 4G10 (α-pY) antibody (Upstate Biotechnology), anti-GAPDH
monoclonal antibody (Fitzgerald), and the anti-IL2Rβ/anti-IL2Rγ chain antibodies (Santa Cruz
Biotechnology).
4.2.3 siRNA-mediated Silencing of ERK1 and ERK2
ERK1 (SMARTpool catalog number M-003592-03-0010) and ERK2 (SMARTpool
catalog number M-003555-04-0010) as well as control non-targeting (siGENOME Non-Targeting
siRNA Pool #1 catalog number D-001206-13-20) siRNA were purchased from Dharmacon.
Transfection of YT cells was carried out by electroporation using the Nucleofection System by
Amaxa according to manufacturer’s instructions. Briefly, YT cells (5x106) were suspended in 100
µl of transfection solution V and transfected with 750 nM of ERK1, 1 µM ERK2, 750 nM of ERK1
and 1 µM ERK2, or 1.750 µM control siRNA using the O-017 program. Transfected cells were
immediately diluted with pre-warmed complete RPMI and cultured for 48 h. Cells were then
quieted for 24 h in 1% FBS media before incubation with or without IL2 as indicated.
4.2.4 In Vitro Dephosphorylation Assay
YT cells (20x106) were incubated with or without 100 nM CA for 15 min prior to
solubilization in lysis buffer (1% Triton X-100, 10 mM Tris-HCl pH 8.0, 50 mM NaCl). Total cell
lysates were incubated without or with 0.5 units of purified PP1 or PP2A (Millipore) at 37 °C for
60 min according to the manufacturer’s instructions. The reactions were stopped by addition of
sample buffer containing 125 mM Tris-HCl, pH 6.8, 10% β-mercaptoethanol, 9.2% SDS, 0.04%
bromophenol blue, 20% glycerol, and boiled for 5 min. Samples were resolved by SDS-PAGE and
phosphorylation of T450 was measured by Western blot analysis.
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4.2

RESULTS

4.2.1 Phosphorylation of T450 IL2R Occurs In Vivo and Displays Rapid Kinetics
To determine whether IL2Rβ is phosphorylated at T450 in response to physiological
stimuli, and kinetic rate compared to tyrosine phosphorylation, YT cells were subjected to an IL2
stimulation time course (0-60 min). Endogenous IL2Rβ was immunoprecipitated and each sample
divided and examined for phosphorylation with either α-pY or α-pT450 IL2Rβ antibodies (Fig.
4.1A). IL2 stimulation resulted in phosphorylation of tyrosine and T450 within 30 seconds and
attained maximal levels at approximately 2.5 minutes. T450 phosphorylation signal continued to
increase and reached a maximum at 10 minutes post IL2 stimulation. A reduction in tyrosine and
T450 phosphorylation began at 30 minutes post-stimulation. In order to evaluate a putative
pleiotropic role of T450 phosphorylation, YT cells were stimulated with IL15, harvested between
0 and 60 min and immunoprecipitated IL2Rβ examined for phosphorylation with α-pT450 IL2Rβ.
IL15 displayed similar phosphorylation profiles compared to IL2. Maximum phosphorylation of
IL2Rβ T450 occurred within 2.5 minutes, and was sustained for 30 minutes (Fig. 4.1B). To
determine whether IL2 and IL15 induced phosphorylation of T450 is isolated to the acute
lymphoblastic lymphoma NK-like cell line, YT, other human malignant hematopoietic cell lines
including the HTLV-1 positive cutaneous T-cell lymphoblast HUT102 [92], cutaneous T-cell
lymphoma HH [93], T-cell chronic lymphocytic leukemia KIT225, HTLV-1 positive T-cell
leukemia MT2 [94], and the T-cell lymphoblastic leukemia SUPT1 were made quiescent by
growing to media exhaustion and then stimulated with IL2 or IL15 for 5 min. Endogenous IL2Rβ
was immunoprecipitated and resolved in SDS-PAGE for analysis through Western blot. Both IL2
and IL15 were able to induce phosphorylation of IL2Rβ at T450 in all human malignant
hematopoietic cell lines (Fig. 4.1C). To test whether T450 is phosphorylated in non-tumorigenic
primary lymphocytes, PHA-activated primary human peripheral blood mononuclear cells
(hPBMCs) were made quiescent and then stimulated with IL2 or IL15 (Fig. 4.1D). Both cytokines
were able to induce IL2Rβ T450 phosphorylation. IL2 and IL15 induced phosphorylation was
detectable within 5 min of stimulation. Phosphorylation induced by IL2 returned to basal levels at
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15 min. These data suggest that IL2Rβ T450 phosphorylation may be important for diverse
biological functions mediated by IL2 and IL15. Thus, the phosphorylation of IL2Rβ T450 occurred
in multiple cell types, including primary human PBMCs, with activation profiles indicating a
general mechanism of IL2Rβ activation.
4.2.2 Inhibition of JAK and MEK Kinases Disrupts IL2 Mediated T450 IL2Rβ
Phosphorylation
To identify the putative kinase(s) responsible for phosphorylating IL2Rβ T450, YT cells
were incubated with inhibitors of candidate serine-threonine kinases prior to IL2 stimulation. The
candidate kinases were chosen based on the main pathways activated by IL2: JAK/STAT, PI3K,
and MEK/ERK. In addition, the intracellular domain of IL2Rβ was analyzed using the
PhosphoMotif Finder tool of the Human Protein Reference Database [95] for consensus
serine/threonine kinase substrate motifs. Of interest were ERK1 and ERK2, which were reported
to phosphorylate proline flanked threonine residues and are activated by IL2. We found that
blockade of JAK activation (tofacitinib) resulted in abrogation of IL2 induced T450
phosphorylation in a dose dependent manner. In contrast, inhibition of PI3K (wortmannin) or PKA
(KT5720) had no visible effect even at high doses (Fig. 4.2A). However, treatment with the highly
specific MEK inhibitor trametinib, resulted in a significant loss of IL2 induced T450
phosphorylation in a dose dependent manner that corresponded with a loss of ERK1/2 activation
(Fig. 4.2B). Interestingly, IL2 induced tyrosine phosphorylation of IL2Rβ was unaffected by
trametinib treatment, although the shift in electrophoretic mobility of the receptor reverted to its
unstimulated form (Fig. 4.2B). Additionally, inhibition of ERK resulted in a reduction of
phosphorylation of IL2 induced T450 Taken together, these results suggest that IL2Rβ T450
phosphorylation is dependent upon IL2 induced activation of the MEK/ERK pathway.
4.2.3 siRNA-mediated Knockdown of ERK1 and ERK2 Inhibits IL2 Induced IL2Rβ T450
Phosphorylation
To confirm their role in phosphorylation of T450, siRNA mediated knockdown of ERK1
and ERK2 was performed in YT cells. First, increasing concentrations (100, 250, and 500 nM) of
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ERK1, ERK2, or non-targeting control siRNA were delivered into YT cells via electroporation in
order to determine the ideal concentration for ERK1/2 knockdown. At 72 h post transfection, cells
were harvested and lysates analyzed by Western blot for ERK1/2 and GAPDH. As shown in figure
4.3A, a reduction of ERK1 and ERK2 was observed with increasing concentrations of their
corresponding siRNA but not with the non-targeting control. We were able to obtain about 1-fold
reduction of ERK1 and ERK2 protein levels relative to GAPDH with 500 nM of siRNA (Fig.
4.3B). For the T450 phosphorylation studies, YT cells were transfected with a combination of
ERK1 and ERK2 or non-targeting siRNA. Cells were stimulated with IL2 for 5 min 72 h posttransfection and phosphorylation of IL2Rβ and STAT5 along with ERK1/2 knockdown was
determined by Western blot analysis of total cell lysates. ERK1 and ERK2 specific siRNA
significantly reduced protein levels of ERK1 and ERK2 as demonstrated in Fig. 4.4A, upper panel.
Concomitantly, knockdown of both ERK1 and ERK2 correlated with the loss of IL2 induced
phosphorylation of IL2Rβ T450 while phosphorylation of STAT5 confirmed successful
stimulation of the cells with the cytokine and total STAT5 and GAPDH confirmed equal loading
of protein. Densitometric analysis of ERK1/2 expression normalized to GAPDH showed about a
0.5-fold decrease of ERK1/2 siRNA treated cells compared to non-targeting control (Fig. 4.4B
lower panel) In addition, we analyzed IL2 induced pT450 signal and we observed a 0.6-fold
reduction in cells transfected with a combination of ERK1/2 siRNA compared to the non-targeting
control (Fig. 4.4C). These findings demonstrate that ERK1 and ERK2 expression has a direct effect
on IL2 induced phosphorylation of IL2Rβ T450. Additionally, the temporal relationship between
IL2 induced phosphorylation of IL2Rβ on tyrosine versus threonine 450 with rapid tyrosine
phosphorylation and more protracted threonine phosphorylation kinetics is consistent with an
activation of the IL2R and the MEK/ERK pathway prior to phosphorylation of IL2Rβ T450 (Fig.
4.1A).
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FIGURE 4.1: Phosphorylation of T450 IL2Rβ displays rapid kinetics and is inducible by
IL2 and IL15 in several malignant hematopoietic cell lines as well as in non-tumorigenic
4

primary lymphocytes. T cells were grown to exhaustion and then stimulated with IL2 (10 IU)
(A) or IL15 (0.49 mg/mL) (B) for the indicated times. C, The indicated cell lines where grown to
exhaustion and then stimulated for 5 min. D, quiescent PHA-activated human PBMCs were
stimulated with IL2 and IL15 and the cells were harvested at the indicated time points. IL2R
was immunoprecipitated (IP), separated by SDS-PAGE, and immunoblotted (IB) as indicated.
Representative data from three independent experiments are shown.
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FIGURE 4.2: Inhibition of JAK, MEK, and ERK kinases inhibits IL2 mediated T450
IL2Rβ phosphorylation. YT (A) cells were grown to exhaustion, treated with increasing
concentrations of the indicated inhibitors for 60 min and then stimulated with or without IL2 (103
IU) for 5 min. Cell lysates or immunoprecipitated (IP) IL2R were separated by SDS-PAGE and
immunoblotted (WB) as indicated.
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Figure 4.3: siRNA mediated silencing of ERK1 or ERK2 in YT cells. A, YT (5x106) cells were
nucleofected with ERK1-specific siRNA, ERK2-specific siRNA, or non-targeting control siRNA
(100-500 nM). 72 h post-nucleofection cells were harvested, cell lysates (10 mg) separated by
SDS-PAGE and analyzed by Western blot (WB) as indicated. Band intensities were normalized to
GAPDH using densitometric analysis and fold decrease plotted for each treatment.
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FIGURE 4.4: Knockdown of ERK1/2 kinases inhibits IL2 mediated T450 IL2Rβ
phosphorylation. A, YT (5x106) cells were nucleofected with ERK1-specific siRNA
(750nM), ERK2-specific siRNA (1mM), a combination of both ERK1 and ERK2-specific
siRNA or with a non-targeting control siRNA (1.75mM). At 72 h post-nucleofection cells were
harvested and incubated with or without IL2 (103 IU) for 5 min at 37 °C. Cell lysates (10 mg)
were separated by SDS-PAGE, and immunoblotted (WB) as indicated. Representative data
from three independent experiments are shown. Band intensities were normalized to GAPDH
using densitometric analysis and fold decrease plotted for each treatment. Values represent the
mean ± S.D of ERK1/2 expression or T450 phosphorylation signal. Statistical significance
was determined using Student’s t test. *, p < 0.05.
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4.2.4 PP1 Negatively Regulates Phosphorylation of IL2Rβ T450
Our group has shown that inhibition of PP1 and PP2A with calyculin A induces
electrophoretic mobility shift in IL2Rβ characteristic of phosphorylated proteins [56]. In the
present study, mass spectrometry analysis of IL2Rβ revealed T450 to be phosphorylated in CA
treated samples. To characterize the effect of PP1 and PP2A inhibition on T450 phosphorylation,
a kinetic analysis of CA treatment was performed. YT cells were treated with 100 nM CA for the
indicated times. IL2Rβ was immunoprecipitated from soluble cell lysates, separated by SDSPAGE, and subjected to Western blot analysis with α-pT450 IL2Rβ antibody (Fig. 4.5A).
Consistent with our mass spectrometry data, CA treatment induces phosphorylation of IL2Rβ
T450 with rapid kinetics. Phosphorylation of T450 was observed as early as 5 min, the signal was
sustained until 15 min and returned to basal levels after 60 minutes post-stimulation. The
membrane was stripped and reprobed for total IL2Rβ to ensure equal gel loading. To elucidate the
primary phosphatase responsible for regulation of IL2Rβ T450 phosphorylation, inhibitors with
opposing specificity toward PP1 or PP2A were investigated. For this analysis, YT cells were left
untreated, stimulated with IL2, or incubated with inhibitors of PP1 (1µM TAU), PP2A (250 nM
OA), PP1/PP2A (100 nM CA), or PP2B (250 nM CSA). Cell lysates were separated by SDSPAGE and phosphorylation of IL2Rβ T450 analyzed by Western blot (Fig. 4.5B). Indeed,
stimulation with IL2 and treatment with OA, CA, and to a lesser extent TAU, but not CSA, resulted
in phosphorylation of IL2Rβ T450. To further differentiate the role of PP2A from PP1 in the
regulation of T450 phosphorylation, an in vitro phosphatase assay was performed. YT cells were
left untreated, stimulated with IL2, or treated with 100 nM CA for 15 min. Cell lysates were
subjected to in vitro dephosphorylation using purified PP1 or PP2A enzymes prior to SDS-PAGE
and Western blot analysis. As shown in Fig. 4.5C, dephosphorylation using purified PP1, but not
PP2A, reversed the IL2 and CA induced phosphorylation of T450. Taken together, these data
indicate that inhibition of PP1 but not PP2A mediates dephosphorylation of IL2Rβ T450 in vivo
and that PP1 directly dephosphorylates it in vitro.
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Figure 4.5: PP1 regulates IL2Rβ T450 phosphorylation. A, YT cells were left untreated or
incubated with CA (100 nM), lysed, IL2Rβ immunoprecipitated (IP) and analyzed through
Western blot (WB) using α-pT450 IL2Rβ. The membrane was stripped and reblotted for total
IL2Rβ as indicated. B, YT cells were left untreated, stimulated with IL2 (104 IU) for 5 min,
treated with TAU (1 mM), OA (250 nM), CSA (250 nM) for 1 h, or CA (100 nM) for 15 min.
Cell lysates were separated by SDS-PAGE, and Western blotted (WB) as indicated. C, YT cells
were incubated in the absence or presence of IL2 (104 IU) for 5 min, or CA (100 nM) for 15
min. Cells lysates were left untreated or subjected to dephosphorylation using 0.5 units of
purified PP1 or PP2A for 60 min at 37 °C before separation by SDS-PAGE and Western blot
analysis as indicated (WB).
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4.2

DISCUSSION
Serine and threonine phosphorylation have been found to elicit positive and negative

regulatory effects on signal transduction [96], hence the importance to have a better understanding
of its functional role in IL2 signaling. In this chapter, the phosphorylation of a specific threonine
residue (T450) in IL2Rβ in response to stimuli by IL2 and IL15 was assessed. The regulatory
pathway governing the phosphorylation and dephosphorylation of such residue in order to describe
the mechanism behind this phenomenon was also investigated. The strategy employed consisted
of cell stimulation with IL2 or IL15 and assessment of phosphorylation by Western blot using our
novel phosphospecific antibody α-pT450 IL2Rβ. To elucidate the regulators of IL2Rβ T450
phosphorylation we used commercially available inhibitors of several kinases activated by IL2
coupled with siRNA knockdown of our main candidate ERK1/2. In addition, inhibitors to different
protein phosphatases revealed two candidates for the regulation of T450 phosphorylation, which
was further specified by in vitro dephosphorylation using purified phosphatases.
Tyrosine phosphorylation of IL2Rβ is mediated by JAKs and has been proven to be
essential for IL2 signal transduction while serine and threonine phosphorylation of the receptor
has only been recently reported to be an important negative regulator of such signaling [56]. Here
we found that IL2Rβ is phosphorylated at T450 in response to both IL2 and IL15 in several
malignant hematopoietic cell lines. In addition, T450 is phosphorylated in non-tumorigenic
primary lymphocytes when stimulated with IL2 or IL15. We also found that treatment with the
highly specific MEK inhibitor trametinib, resulted in loss of IL2 induced T450 phosphorylation in
a dose dependent manner that corresponded to loss of ERK1/2 activation (Fig. 4.2B). siRNA
mediated knockdown of ERK1 and ERK2 correlated with the loss of IL2 induced phosphorylation
of IL2Rβ T450, confirming thus a role for these kinases in such phosphorylation. In addition,
treatment with OA, CA, and to a lesser extent TAU, but not CSA resulted in phosphorylation of
IL2Rβ T450. An in vitro dephosphorylation revealed that PP1 was able to reverse IL2 and CA
induced phosphorylation of T450.
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In summary, phosphorylation of T450 is induced by IL2 and IL15 with rapid kinetics
attaining peak levels at 2-10 min. In addition, IL2Rβ T450 phosphorylation is dependent upon IL2
induced activation of the MEK/ERK pathway and ERK1 and ERK2 expression has a direct effect
on IL2 induced phosphorylation of IL2Rβ T450 while inhibition of PP1 mediates
dephosphorylation of IL2Rβ T450 in vivo and directly dephosphorylates it in vitro. Taken together,
these data suggest that IL2Rβ T450 phosphorylation may be important for diverse biological
functions mediated by IL2 and IL15 with activation profiles indicating a general mechanism of
IL2Rβ activation. Identifying the functional role of IL2Rβ phosphorylation will take us one step
closer to understanding IL2 singling and is the subject of the next chapter.
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CHAPTER 5
IL2R T450 Phosphorylation Modulates IL2 Signaling
and STAT5 Transcriptional Activity
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5.1

INTRODUCTION
IL2 induced tyrosine phosphorylation of IL2Rβ allows for recruitment and docking of

different proteins to become tyrosine, serine, and threonine phosphorylated. It has been proven to
be an important mechanism of activation of JAK/STAT, PI3K and MEK/ERK signaling pathways
and a vehicle for cell proliferation. Threonine phosphorylation of the receptor on the other hand
has only been recently described. Two sites, T79 and T256 were reported to be phosphorylated
through proteomic discovery-mode mass spectrometry [83] while our group confirmed through
phosphoamino acid analysis threonine phosphorylation in response to IL2 stimulation and CA
treatment [56]. To our knowledge, there are no reports of site specific methods of identification of
threonine phosphosites on IL2Rβ, much less characterization and description of functional role. In
this part of our study, we sought to investigate the functional role of IL2Rβ T450 phosphorylation.
Ross et al. reported that serine and threonine phosphorylation appear to act as negative regulators
for IL2 signaling. Blocking the serine/threonine phosphatase PP2A increased serine/threonine
phosphorylation and reduced IL2 induced tyrosine phosphorylation of the β subunit [56]. Here we
provide evidence of T450 phosphorylation in response to IL2 and IL15 which was reduced by
blocking ERK1/2 activation using the MEK specific inhibitor trametinib or the ERK specific
inhibitor FR18024 (ERK inhibitor II). IL2 induced tyrosine phosphorylation of the receptor was
found to be independent of T450 phosphorylation since blocking the latter did not have a
noticeable effect on the former (Fig. 4.1), which lead us to believe T450 phosphorylation might
play a positive regulatory role on IL2 signal transduction.
In order to determine the role of IL2 induced IL2Rβ T450, a HEK293 reconstitution system
was employed using either WT or a phospho-deletion (T450A) mutation of IL2Rβ. We assessed
the effect of IL2 induced T450 phosphorylation in the assembly of the IL2R complex and the
activation of key signaling molecules by immunoprecipitation and Western blot analysis. In
addition, we used a STAT5B luciferase reporter assay in order to assess putative transcriptional
activity differences caused by the phospho-deletion mutant compared to WT. We show that
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phosphorylation of T450 is important for IL2R complex formation and full activation of IL2
signaling which leads to impaired STAT5B transcriptional activity.
5.2

MATERIALS AND METHODS

5.2.1 Plasmids, Site-directed Mutagenesis, and Transfection of HEK293 Cells
The pcDNA3.1/GS human IL2Rβ and IL2Rγ expression plasmids were purchased from
Invitrogen. The pcDNA3.1 human JAK3 was obtained as previously described [97]. STAT5b
cDNA (OriGene) was generated as previously described [86]. The β-casein-lulciferase reporter
plasmid was used as reported previously [89]. The pCMV-β-galactosidase expression plasmid is
described in [98]. Mutant forms of IL2Rβ were prepared using the QuikChange site-directed
mutagenesis kit (Stratagene) according to the manufacturer’s instructions. The primers used for
the IL2Rβ mutation were as follows: T450A (5'- TGGGGCCTCCCGCCCCAGGAGTC -3');
T450E (5'- CCCTGGGGCCTCCCGAGCCAGGAGTCCCAGA -3'). All subclones and
mutations were verified by DNA sequencing at the Genomic Analysis Core Facility of the
Border Biomedical Research Center at The University of Texas at El Paso. Transient
transfections of HEK293 cells were performed with Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions.
5.2.2 Solubilization of Proteins, Immunoprecipitation, and Western Blot Analysis
Cells were pelleted, lysed and subjected to immunprecipitation and Western blot analysis
as described in section 2.2.2. For reblotting, membranes were incubated with stripping buffer as
described in section 3.2.5. Immunoprecipitation was performed using the α-IL2Rβ monoclonal
antibody 561 [91]. The anti-phospho-Tyr694 STAT5a and Tyr699 STAT5b (pYSTAT5) monoclonal
antibody, α-STAT5 polyclonal antibody, α-phospho-p44/42 MAPK (ERK1/2) Thr202/Tyr204
polyclonal antibody, α-p44/42 MAPK (ERK1/2) polyclonal antibody, α-phospho-AKT and αAKT antibodies were purchased from Cell Signaling Technology and were used according to the
manufacturer’s protocol along with anti-phosphotyrosine monoclonal 4G10 (α-pY) antibody
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(Upstate Biotechnology), anti-GAPDH monoclonal antibody (Fitzgerald), and the antiIL2Rβ/anti-IL2Rγ chain antibodies (Santa Cruz Biotechnology).
5.2.3 Luciferase/β-galactosidase
Subconfluent HEK293 cells in 10-cm dishes were transfected with the following plasmids:
WT or mutant IL2Rβ (6µg), γc (6 µg), JAK3 (0.5 µg), STAT5B (3 µg), β-casein-luciferase reporter
(3 µg), and pCMV-β-gal (1 µg). Cells were stimulated with or without 104 IU/ml IL2, transferred
to 96-well plates (10,000 cells per well) and incubated for 3 h at 37 °C. Luciferase and β-gal
activities were measured using ONE-Glo Luciferase and Beta-Glo Assay systems (Promega)
respectively following the manufacturer’s instructions.
5.3

RESULTS

5.3.1 Phosphorylation of T450 is Required for Optimal IL2 Receptor Complex Formation
IL2 promotes the formation of a heterotrimeric receptor complex that consists of two
essential subunits, IL2Rβ, the γc, and the affinity modulating subunit α. Failure in the assembly of
IL2Rβ and γc upon stimulation of IL2 results in the blockade of downstream signaling components
[99] [100] [56]. Previous work from our group had shown that CA induced serine and threonine
phosphorylation disrupted the IL2 induced IL2R complex formation and activation of downstream
targets [56]. To determine the role of IL2 induced IL2Rβ T450 phosphorylation in the assembly
of the IL2R complex, a HEK293 reconstitution system was employed using phospho-deletion
(T450A) mutation of IL2Rβ. Plasmids encoding γc, JAK3, and STAT5B were co-transfected into
HEK293 cells with WT or T450A forms of IL2Rβ. At 48 h after transfection, cells were made
quiescent and then left untreated or stimulated with IL2 for 10 min. The IL2Rβ subunit was
immunoprecipitated from soluble lysates and probed for the association of γc, JAK3 and STAT5B
by Western blot analysis. IL2 stimulation resulted in co-immunoprecipitation of JAK3, STAT5B
and γc with WT IL2Rβ. Importantly, IL2 induced association of JAK3, STAT5 and γc with the
T450A mutated β was reduced as shown in the co-immunoprecipitation studies (Fig. 5.1A). To
further investigate the effects of the T450 phospho-deletion mutant on IL2 signaling, we analyzed
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whole cell lysates for activation of key proteins of each of the IL2 induced pathways: JAK/STAT,
PI3K, and MEK/ERK (Fig. 5.1B). We found constitutive STAT5 tyrosine phosphorylation in cells
transfected with γc, JAK3, STAT5 and WT IL2Rβ. However, such phosphorylation appears to be
slightly induced by IL2 stimulation. Importantly, tyrosine phosphorylation of STAT5 was lost in
cells transfected with the phospho-deletion mutant (T450A). Activation of the PI3K pathway was
assessed in terms of phosphorylation of its downstream target AKT. IL2 induced phosphorylation
of AKT was observed in cells transfected with WT but not in cells expressing the T450A mutant.
Similarly, IL2 induced phosphorylation of ERK1/2 was detected in cells transfected with
the WT receptor, but not with the phospho-deletion mutant. These results suggest that
phosphorylation of T450 is required for the assembly of the IL2Rβ complex in addition to
regulating the phosphorylation of the downstream signaling molecules STAT5, AKT, and
ERK1/2.
5.3.2 Phosphorylation of T450 is Important for Maximum IL2 Induced STAT5B
Transcriptional Activity
STAT5A and STAT5B transcription factors become activated in response to several
growth factors and cytokines, including IL2, which induces tyrosine phosphorylation of the
receptor and provides docking sites for STATs to bind through their SH2 domains. Bound STATs
become activated through tyrosine and serine phosphorylation, form dimers, and translocate to the
nucleus to activate genes related to differentiation and proliferation of cells (31). To determine if
phosphorylation of IL-2Rβ T450 is important for STAT5B transcriptional activity in vivo,
luciferase reporter assays were performed using the HEK293 reconstitution system. Plasmids
encoding γc, JAK3, and STAT5B were co-transfected into HEK293 cells with WT, T450A, or
T450E forms of IL-2Rβ, along with a β-casein-firefly luciferase reporter, and a β-gal reporter
construct. At 48 h post-transfection, cells were made quiescent and then left untreated or stimulated
with IL-2 for 3 h. Luciferase activity was normalized to β-gal activity and change calculated in
reference to IL-2 stimulated WT IL-2Rβ samples. Upon IL-2 stimulation, the IL-2Rβ T450A
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Figure 5.1: IL2Rβ T450 phosphorylation is a positive regulator for IL2 complex stability
and activation of signaling molecules in reconstituted HEK293 cells. A, HEK293 cells
were transfected with γc, JAK3, STAT5B and IL2Rβ (WT or T450A), incubated for 48 h in
complete media, followed by incubation 48 h in 1% FBS media. The cells were then
stimulated without (-) or with IL-2 (+) for 10 min, cells were lysed, the IL-2Rb was
immunoprecipitated (IP) before separation by SDS-PAGE and Western blot analysis as
indicated (IB). Total cell lysate (10mg) was also probed (B) by Western blot with the
indicated antibodies.
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Figure 5.2: IL2Rβ T450 phosphorylation is required for maximal IL2 induced STAT5B
transcriptional activity. HEK293 cells were transfected with IL2Rβ (WT or T450A), γc, JAK3,
STAT5B, β-casein-luciferase, and pCMV-β-galactosidase. 48 h post-transfection, cells were
incubated with or without IL2 for 3 h and luciferase activity measured and normalized to β-gal
activity. Each treatment was performed in triplicates. Results are presented as the mean ± S.D.
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mutant showed a 40% decrease in STAT5B luciferase reporter activity relative to WT IL-2Rβ (Fig.
5.2). Additionally, we found that the phospho-mimetic mutation (T450E) displayed transcriptional
activity comparable to wild type. These data suggests that IL-2Rβ T450 phosphorylation is
important for effective transduction of IL-2 signal and STAT5B transcriptional activity.
5.4

DISCUSSION
In an attempt to determine the functional role of phosphorylation of IL2Rβ T450, we

reconstituted the IL2R system in HEK293 cells. We assessed the differences in response to IL2 of
the WT receptor versus the T450A mutant by co-immunoprecipitation and Western blot analysis.
In addition, STAT5B transcriptional activity in response to IL2 signaling through the WT receptor
versus the phospho-deletion mutant was assessed by using a luciferase reporter assay.
T450 is located in the H region of the IL2Rβ, which also contains Y392 and Y510. Upon
stimulation with IL2, these tyrosines become phosphorylated and serve as docking sites for STAT5
[20] [37]. Studies in mice showed that removal of the H region results in a lack of NK cells, γδ T
cells, and T cells that fail to respond to low concentrations of IL2, which results in downregulation
of IL2Rα [40]. By using IL2Rβ chimeras it was later shown that although STAT5 is able to become
activated, deleting the region between Y392 and Y510, where T450 is located, abolishes
expression of IL2Rα [42]. This suggests a positive regulatory role for that region of the receptor.
In line with those studies, we found a putative positive regulatory role for the
phosphorylation of T450. It appears to be important for maximal IL2 induced IL2R complex
formation and activation of the downstream signaling molecules STAT5B, AKT, and ERK1/2.
Such impaired activation coincides with the observed decrease in STAT5B transcriptional activity
as demonstrated in the luciferase reporter assay. Taken together, this data provides evidence that
in addition to tyrosine phosphorylation, threonine phosphorylation of IL2Rβ regulates IL2 signal
transduction.
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CHAPTER 6
Overview and Future Directions
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6.1

OVERVIEW
Homeostasis of the immune system is required for proper defense against pathogenic insult.

IL2 is essential to maintain homeostasis and its signaling provides activation of T, B, and NK cells.
IL2 signal transduction occurs through the IL2R, which becomes tyrosine phosphorylated upon
induction with the cytokine, providing a site for binding and activation of downstream molecules.
Serine and threonine phosphorylation of the receptor has been shown to occur upon inhibition of
the serine/threonine phosphatases PP1 and PP2A. Such phosphorylation was implicated in
negative regulation of IL2 signaling and formation of the IL2R complex. We sought to investigate
the putative regulatory role that specific serines and threonine have in IL2 signaling.
The first objective of this dissertation was to map the serine and threonine phosphorylation
sites on IL2R. The strategy of large-scale immunoprecipitation of  followed by identification of
phosphopeptides through LC-MS/MS revealed thirteen sites to be differentially phosphorylated in
IL2R in response to diverse stimuli (Figures 2.1, 2.2, 2.3 and Table 2.1). We identified S405
and T450 to become phosphorylated in response to IL2 stimulation. In addition, serines 267,
268, 432, 484, and 512 as well as threonine 256, 308, 394 and 450 were found to be
phosphorylated with CA treatment. The novel IL2 inducible threonine 450 and serine 512 were
chosen for further examination and amino acid sequence alignment of the region surrounding each
of the phosphosites from different organisms revealed conservation among different species.
Interesting, S512 was found to be more highly conserved than T450. Thus, we identified a novel
IL2 inducible threonine phosphorylation site in human IL2Rβ.
In order to verify that IL2Rβ is phosphorylated at T450 and S512 and to investigate the
regulatory role of this phosphorylation sites, phospho-specific polyclonal antibodies were
generated. The strategy for characterization of the antibodies including ELISA, SPR, dot blot, and
Western blot of immunoprecipitated IL2Rβ revealed that both -pT450 and -pS512 IL2R
antisera preferentially recognize their phosphorylated peptide; they show higher binding response,
stronger binding kinetics and functional affinity to and are specifically blocked by phospho- but
not non-phosphopeptide. In addition, both -pT450 and -pS512 IL2R proved to be useful for
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western blot analysis of immunoprecipitated protein and total cell lysates, which provided us with
an excellent tool for the characterization of our phosphosites.
In the second part of our study, we assessed phosphorylation of T450 in IL2Rβ in response
to stimuli by IL2 and IL15. We also investigated the regulatory pathway governing the
phosphorylation and dephosphorylation of such residue. The strategy employed consisted on
stimulation of cells with IL2 or IL15 and assessment of phosphorylation through Western blot
using our phosphospecific antibody α-pT450 IL2Rβ. To elucidate the regulators of IL2Rβ T450
phosphorylation we used commercially available inhibitors of several kinases activated by IL2
coupled to siRNA knockdown of our main candidate ERK1/2. In addition, inhibitors to different
protein phosphatases revealed two candidates for the regulation of T450 phosphorylation, which
was further specified by in vitro dephosphorylation using purified phosphatases. We found that
IL2Rβ is phosphorylated at T450 in response to both IL2 and IL15 in several malignant
hematopoietic cell lines and in non-tumorigenic primary lymphocytes. We also found that
treatment with the specific MEK inhibitor trametinib, resulted in loss of IL2 induced T450
phosphorylation in a dose dependent manner that corresponded to loss of ERK1/2 activation (Fig.
4.2B). Inhibition of ERK by FR180204 also resulted in loss of IL2 induced T450 phosphorylation.
siRNA mediated knockdown of ERK1 and ERK2 inhibited IL2 induced IL2Rβ T450
phosphorylation. To further delineate the regulation of T450 phosphorylation, cells were treated
with inhibitors against protein phosphatases and the data indicate that inhibition of PP1 but not
PP2A or PP2B induces phosphorylation of IL2Rβ T450 in vivo and that PP1 directly
dephosphorylates it in vitro.
Taken together, these data suggest that IL2Rβ T450 phosphorylation may be important for
diverse biological functions mediated by IL2 and IL15 with activation profiles indicating a general
mechanism of IL2Rβ activation. To determine the functional role of phosphorylation of IL2Rβ
T450, we reconstituted the IL2R system in HEK293 cells and assessed the differences in response
to IL2 of the WT receptor versus the T450A mutant by co-immunoprecipitation and Western blot
analysis. In addition, STAT5B transcriptional activity in response to IL2 signaling through the WT
97

receptor versus the phospho-deletion and phospho-mimetic mutant was assessed by using a
luciferase reporter assay. We found that phosphorylation of IL2Rβ T450 is important for
maximum IL2 induced IL2R complex formation and activation of the downstream signaling
molecules STAT5B, AKT, and ERK1/2. In addition, we observed a decrease in STAT5B
transcriptional activity as demonstrated in the luciferase reporter assay. Taken together, this data
provides evidence that in addition to tyrosine phosphorylation, threonine phosphorylation of
IL2Rβ regulates IL2 signal transduction.
In conclusion, we were able to identify novel phosphosites in IL2R and successfully
generated and characterized polyclonal antibodies for two of those sites. The novel phosphosite
T450 is IL2 and IL15 inducible and regulated by ERK and PP1. Phosphorylation of T450 is
important for IL2R complex formation and effective IL2 signal transduction which influences
STAT5 transcription activity.

6.2

FUTURE DIRECTIONS

Determine involvement of T450 phosphorylation in disease
Dysregulated phosphorylation of proteins plays a critical role in several cancers, including
hematopoietic malignancies. Therefore, the T450 phosphorylation status could be explored in
leukemia and lymphoma patient samples as well as samples from patients with autoimmune
diseases like lupus and rheumatoid arthritis. Cell lysates from these samples could be assessed for
phosphorylation of T450 by Western blot using our novel phosphospecific antibodies.
Comparative analysis of IL2Rβ T450 and tyrosine phosphorylation
Analysis of downstream effects of T450 compared to tyrosine phosphorylation of the β
subunit of the receptor can be performed using threonine and tyrosine phospho-deletion mutants.
Tyrosines 338, 392, and 510 could be mutated to phenylalanine alone, or in combination with a
T450A mutant and its effects compared to each other or to wild type.
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Investigate the functional role of S512 phosphorylation on IL2 signal transduction
Regulation of IL2 signaling has yet to be explored for S512. Studies performed indicate
that S512 does not become phosphorylated with IL2 or IL15 stimulation, however treatment with
CA does result in phosphorylation of the site. Crosstalk between IL2Rβ and the T-cell receptor
could be explored by assessing S512 phosphorylation during T-cell activation. In addition,
phosphorylation of this site in response to other stimulants including G-protein coupled receptor
agonists could be explored.
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